curriculum vitae - Institut de la Màcula [PDF]

C. Vitae Jordi Monés 1

CURRICULUM VITAE, July, 2016

Jordi M. Monés PERSONAL DATA. 1. EDUCATION / QUALIFICATIONS 2. PRESENT PROFESSIONAL POSITIONS 3. PAST POSITIONS 4. INTERNATIONAL AWARDS 5. ADVISORY BOARDS and RESEARCH COMMITTEES 6. GRANTS 7. CLINICAL TRIALS 8. SCIENTIFIC PUBLICATIONS 9. SCIENTIFIC PRESENTATIONS 10. TEACHING ACTIVITIES and INVITED LECTURES 11. COLLABORATION IN JOURNALS EDITION and REVIEWER 12. THESIS 13. SCIENTIFIC SOCIETIES MEMBERSHIP 14. LANGUAGES

C. Vitae Jordi Monés 2

PERSONAL DATA: Name:

Jordi Manel Monés i Carilla (Jordi M. Monés)

Address:

Institut de la Màcula Centro Médico Teknon Àrea Vilana. Building 90 Vilana 12, 08022 Barcelona SPAIN

1.

Telephone

+34 93 5950155

Fax

+34 93 5950345

E- mail:

[email protected]

Web:

www.institutmacula.com

Date of Birth:

Barcelona, June 25, 1961.

EDUCATION / QUALIFICATIONS: 1.1. 09/1979

-

06/1985:

LICENCIATE

IN

MEDICINE

AND

SURGERY.

Qualification: Excellent. University of Barcelona. Barcelona, SPAIN. 1.2. 01/1986: SPANISH NATIONAL BOARD EXAMINATION for a Residency Position M.I.R.1985/6: National classification number: 84. 1.3. 1/86 - 12/1989:

RESIDENCY

IN

OPHTHALMOLOGY, (Opthalmologist

M.I.R.) Barraquer Institute, Barcelona, SPAIN. 1.4. 1/1990 - 06/1991:

RESEARCH FELLOWSHIP

IN OPHTHALMOLOGY

(RETINA SERVICE). The Massachusetts Eye and Ear Infirmary, Harvard University. Boston, U.S.A.

C. Vitae Jordi Monés 3

1.5. 07/1991 - 07/1992: SURGICAL VITREORETINAL FELLOWSHIP. CLINICAL AND SURGICAL RETINA FELLOWSHIP. Retina Department, Hospital San José. Instituto Tecnológico y de Estudios Superiores de Monterrey (ITESM). Monterrey, MEXICO. 1.6. 06/2010 - 06/2012: DOCTORAL THESIS, Ph.D. Degree. DOCTOR IN MEDICINE AND SURGERY, Qualification: Cum Laude. University of Barcelona, SPAIN. 2.

PRESENT PROFESSIONAL POSITIONS: 2.1. CURRENT: 2.1.1. M.D., Ph.D., Opthalmologist, Macula and Vitreorretinal Specialist and Researcher. 2.1.1.1.

Founder and Director of the Institut de la Màcula Centro Médico

Teknon, Àrea Vilana, Building 90, Vilana 12, 08022 Barcelona, since 2007. 2.1.1.2.

Director, principal investigator and one of the founders of the

Barcelona Macula Foundation: Research for Vision, since 2011. 2.1.1.3.

Elected Coordinator of the Specialty of Ophthalmology at the

Centro Médico Teknon, since 2010 2.1.1.4. of

Institut de la Màcula i de la Retina Acredited site of the network excellence

in

research,

European

Vision

Institute

www.europeanvisioninstitute.org/ 2.1.1.5.

Member of the Steering Committee at the International

Multicenter Clinical Trials Proxima A and Proxima B on Geographic Atrophy. Roche, Basel, Switzerland 2.1.1.6. Member of the Steering Committee at the International Multicenter Clinical Trials Brighter and Crystal. Novartis.

C. Vitae Jordi Monés 4

2.1.2. Scientific Advisory Boards 2.1.2.1.

Member of the Scientific Advisory Board of AMD international

Alliance 2.1.2.2.

Member of the Region Europe Ophthalmics Network (REONET)

advisory board, Novartis 2.1.2.3.

Member of the European Advisory Board on Retinal Vein

Occlusion, ERAB, Allergan Inc 2.1.2.4.

Scientific Advisor of Opththech Inc, New York USA

2.1.2.5.

Scientific Advisor of Notalvision Inc, Tel Aviv, Israel

2.1.2.6.

Member of the International Advisory Board for Eylea® (VEGF-

Trap eye) Bayer Schering Pharma 2.1.3. Other positions: 2.1.3.1.

Member of the Board of Directors of Futbol Club Barcelona and

Responsible of the Medical Department and Performance from 20032005, and 2010-2015. 2.1.3.2.

Member of the Board of Directors, Comissioner FC Barcelona

Universitas and Responsible for the Sport Sciences Department, since 2015. 3.

PAST POSITIONS: Consultant as Vitreoretinal Specialist Ophthalmologist in: 3.1. Institut de Microcirurgía Ocular de Barcelona. (April 1993 -December 2006) 3.2. Hospital de la Creu Roja de Barcelona (1995 - Nov 2004), Consultant Ophthalmology Service. Vitreoretinal Surgery. 3.3. Associate Profesor Universitat Autònoma de Barcelona in: (2003 - 2006) Cátedra (Professorship) Institut de Microcirurgia Ocular de Barcelona

C. Vitae Jordi Monés 5

Universitat Autónoma de Barcelona 3.4. Member of the Board of Directors (Junta Directiva) of FUTBOL CLUB BARCELONA. Responsible of the Medical and Sport Medicine Department of Futbol Club Barcelona. June 03 - June 05 3.5. Elected Coordinator of the Specialty of Ophthalmology at the Centro Médico Teknon. Feb 10 - Feb 12 Main Fields of professional interests: His research particular fields of interest are macular diseases, choroidal neovascularization, macular degeneration, antiangiogenic therapy, anti PDGF therapy, geographic atrophy, retinal degeneration, retinal transplant, stems cells, gene therapy, macular edema, and vitreoretinal and macular surgery. 4.

INTERNATIONAL AWARDS: 4.1. Co-Winner

of

the

INTERNATIONAL

AWARD

OF

EXPERIMENTAL

SURGERY Banc de Sabadell, Acadèmia de Medecina de Barcelona, i Col.legi Oficial de Metges de Barcelona,

with the Research Project:

"Photodynamic Therapy of the Experimental Posterior Malignant Melanoma" (Massachusetts Eye and Ear Infirmary, Harvard University, Boston, USA. Director of the Project: Evangelos Gragoudas MD). Barcelona, June 18, 1991. 4.2. Premi a la Recerca Científica en DMAE. Associació Discapacitat Visual de Catalunya. 30 Novembre 2011 4.3. Academy's Achievement Award 2015. American Academy of Ophthalmology. 5.

ADVISORY BOARDS AND RESEARCH COMMITTEES 5.1. 1999: Rotating Member of

Study Advisory Group of the “Randomized,

Placebo-Controlled, Masked, Multicenter, Phase III b Study of the Treatment of the Subfoveal Neovascularization Secondary to Age-Related Macular

C. Vitae Jordi Monés 6

Degeneration and pathologic myopia Using Photodynamic Therapy with Liposomal BPD-MA

Verteporfin”

Institut de

Microcirurgia

Ocular de

Barcelona. 5.2. 2000:

Rotating Member of

Study Advisory Group of the “Photodynamic

Therapy using Verteporfin Study VER, VIO and VIM”. Institut de Microcirurgia Ocular de Barcelona. 5.3. 2003: Member of the International Consultant Committee for Research in AMD, Novartis International, Basel, Switzerland. 5.4. 2003 – 2005: Member of the International Council for Research of Retinal Diseases of Eyetech Co. New York, USA 5.5. 2003 – Ongoing: Scientific Consultant of Notalvision, Co. Tel-Aviv, Israel. 5.6. 2003 – 2006: Member of the Macula Society Research Committee 5.7. 2008 Allergan advisory board. Annual Meeting Association for Research in vision and ophthalmology, Fort Lauderdale, USA. May 1-5 2008 5.8. 2008 Advisory Board Meeting Ophthotech for new treatments for exudative and Dry AMD London, 30 and 31 October, London 5.9. 2008 Advisory board Allergan for Posurdex device for the treatment of macular edema secondary to retinal vein occlusion and diabetic macular edema. American Academy of Ophthalmology, November 9. Atlanta, USA 5.10.

2008

Advisory

Board

for

Preferential

Hyperacuity

Perimeter.

Notalvision, Israel. 5.11. 6.

(from 2008 please see in section 11.2)

GRANTS: 6.1. FUNDACIÓN RICH (Madrid, Spain): Year 1990, 1.700.000 ptas for 1 year of Vitreoretinal Researh Fellowship in the Massachusetts Eye and Ear Infirmary, Harvard University, Boston USA.

C. Vitae Jordi Monés 7

6.2. Beca FISS, Ministerio de Sanidad y Consumo. 1991. 7.

CLINICAL TRIALS 7.1. 1989: Principal Investigator of a multicentric, ranndomized, doble-masked clinical trial with 60 patients enrolled "Diclofenac colirio versus Dexametasona colirio en el Tratamiento de Estados Inflamatorios no Quirúrgicos del Segmento Anterior del Ojo sin Infección”. Centre d’Oftalmologia Barraquer. 7.2. 1997 - 2003: Principal Investigator of a “Randomized, Placebo-Controlled, Masked, Multicenter, Phase III Study of the Treatment of the Subfoveal Neovascularization Secondary to Age-Related Macular Degeneration Using Photodynamic Therapy with Liposomal BPD-MA Verteporfin”. Institut de Microcirurgia Ocular de Barcelona. 7.3. 1998 - 2002: Principal Investigator of a “Randomized, Placebo-Controlled, Masked, Multicenter, Phase III b Study of the Treatment of the Subfoveal Neovascularization Secondary to Age-Related Macular Degeneration and pathologic myopia Using Photodynamic Therapy with Liposomal BPD-MA Verteporfin”. Institut de Microcirurgia Ocular de Barcelona. 7.4. 2001 - 2004: Principal Investigator of the Study VER: “Multicenter, Randomized, Parallel Group, Double Mask, Controlled Phase IIIb, 2-year Study comparing the Efficacy and Safety of VISUDYNE TM Therapy with Early Retreatment to Standard Treatment in Predominantly Classic Subfoveal Choroidal Neovascularization”. Institut de Microcirurgia Ocular de Barcelona. 7.5. 2001 - 2004: Principal Investigator of the Clinical Trial: “Eyetech Pharmaceuticals Phase II/III Clinical Trial with Anti-VRGF Pegylated Aptamer (EYE001) in patients with Exudative Age-Related Macular Degeneration”. Institut

de

Microcirurgia

Ocular

de

Barcelona

7.6. 2001: Principal Investigator of the Clinical Trial: Prospective Clinical Trial of VisionCare Ophthalmic Technologies Inc’s Implantable Miniature Telescope

C. Vitae Jordi Monés 8

(IMTTM) for Patients with Age-Related Macular Degeneration” Institut de Microcirurgia Ocular de Barcelona. 7.7. 2003 - 2005: Principal Investigator of the Clinical Trial: “An Evaluation of Safety and Efficacy of Anecortave Acetate Sterile Suspension Following SubTenon’s Injections for the Inhibition of Neovascularization in Patients With Exudative Age-Related Macular Degeneration”. Institut de Microcirurgia Ocular de Barcelona. 7.8. 2004 - 2005: Evaluation

for

Principal Investigator, Preferential Hyperacuity Perimetry Treatrment

with

Photodynamic Therapy of

choroidal

neovascularization. Institut de Microcirurgia Ocular de Barcelona. 7.9. 2005 - 2006: Co-Investigator, Estudio multicéntrico, fase III, enmascarado, aleatorizado, controlado con simulador, con una duración de 6 meses (con extensión abierta de 6 meses) para evaluar la seguridad y eficacia del sistema aplicador DEX PS DDS (Sistema de liberacion del fármaco dexametasona en el segmento posterior) de 700 microgr y 350 microgr en el tratamiento de pacientes con edema macular después de la oclusión de la vena central de la retina u oclusión de la rama de la vena central de la retina. Institut de Microcirurgia Ocular (IMO) 7.10.

2005 - 2006: Principal Investigator, “ENSAYO fase 3B, aleatorizado,

controlado con tratamiento activo, doble ciego, con simulación simple, multicéntrico, comparativo y de grupos paralelos, para comparar la seguridad y la eficacia de inyecciones intravítreas de Macugen  administradas cada 6 semanas durante 54 semanas (que pueden ampliarse hasta 102 semanas si está indicado) más terapia fotodinámica (TFD) simulada, frente a Macugen  más TFD con VISUDYNE, en sujetos con neovascularización coroidea (NVC) subfoveal predominantemente clásico secundaria a la degeneración macular relacionada con la edad (DMAE)” estudio 206207-009-00 7.11.

2005 - 2006: Co-investigator. VERTA V1. Institut de Microcirurgia

Ocular (IMO), Novartis EudraCT: 2005-001324-36

C. Vitae Jordi Monés 9

7.12.

2005 - 2006: Principal Investigator, Evaluación

internacional de la

carga de enfermedad de la degeneración macular exudativa subfoveal asociada a la edad. Institut de Microcirurgia Ocular (IMO)

Pfizer/

Covance

SOA/COV 2627/ BC 100425 7.13.

2005: Principal Investigator, Estudio de fase III, multicéntrico,

aleatorizado, controlado, con doble enmascaramiento de lactato de escualamina

(MSI-1256F)

en

inyección

para

el

tratamiento

de

la

neovascularización coroidea subfoveal asociada a degeneración macular asociada a la edad. Institut de Microcirurgia Ocular (IMO), Genaera Corporation, MSI-1256F-302 7.14.

2005 -2006: Principal investigator. Ensayo de reducción de riesgo con

acetoato de anecortave (AART) Evaluación de la eficacia y seguridad de la administración yuxtqexcleral posterior de acetato de anecortave para suspensión depot ( 15mg o 30mg ), comparado con la administración sdimulada en pacientes ( participantes en el estudi "A" o en esl estudio "B") con riesfgo de desarrollar neovasc coroidea (CNV ) con amenaza a la visión debido a degeneración macular asociada a la edad ( AMD ) Alcon C-02-60 7.15.

2005 - 2006: Pegaptanib en DMAE exudativa temprana comparada con

DMAE exudativa no temprana. 7.16.

2005 - 2006: Ranibizumab Estudio EXCITE en DMAE exudativa

7.17.

2007 - 2009: Ongoing Promoter and Principal Investigator Raneovasc:

ensayo clínico de fase ii, prospectivo, controlado, abierto, aleatorizado con grupos paralelos para comparar la seguridad y la eficacia del ranibizumab en monoterapia frente a la combinación con

terapia fotodinámica con

verteporfina (TFDV) en pacientes con neovascularización coroidea (NVC) subfoveal secundaria a la degeneración macular asociada a la edad (DMAE) 7.18.

2008 – 2009: Principal Investigator Estudio de fase 3, aleatorizado,

doble enmascarado, con asignación paralela de bevasiranib sódico intravítreo

administrado

cada

8

ó

12

semanas

como

terapia

de

C. Vitae Jordi Monés 10

mantenimiento tras 3 inyecciones de Lucentis®, comparado con monoterapia con Lucentis® cada 4 semanas en pacientes con Degeneración Macular Exudativa Asociada a la Edad. Promotor: OPKO Health. 7.19.

2008-2009: Co-investigator Estudio VIEW-2. Estudio de fase 3,

randomizado, doble enmascarado, con grupo control, para evaluar la eficacia y seguridad de inyecciones intravítreas repetidas de VEGF-Trap en pacientes con degeneración macular asociada a la edad exudativa. Promotor: Bayer. Investigadors: Lluis Arias, Jordi Monés 7.20.

2008-2009: Co-investigator Estudio TG-MV-007. Estudio de fase 3,

multicéntrico, con doble enmascaramiento, controlado con placebo y aleatorizado de la inyección intravítrea de microplasmina para el tratamiento no

quirúrgico

de

la

adherencia

vitreomacular

focal.

Promotor:

Thrombogenics. Investigadors: Lluis Arias, Jordi Monés 7.21.

2009: Principal investigator and protocol co-designer. A phase 1 study

to establish the safety and tolerability of ARC1905 (anti-c5 aptamer) in subjects with dry age-related macular degeneration. Principal investigator: Jordi Monés. Co-investigators: Lluis Arias, Marc Biarnés. 7.22.

2010: Principal investigator and protocol co-designer: An open-labeL

investigator research grant trial Phase II to establish the safety of intravitreous injections of E10030 (anti-PDGF pegylated aptamer) given in combination with Lucentis® in NON RESPONDERS subjects with neovascular age-related macular degeneration. Protocol Number – E10030-001. Investigators: Jordi Monés 7.23.

2010: Principal investigator “Ensayo Fase II, randomizado, doble

enmascarado, controlado, para establecer la seguridad y la eficacia de inyecciones

intravítreas

de

E10030

(aptámero

pegilado

anti-PDGF)

administrado en combinación con Lucentis® en sujetos con Degeneración Macular Asociada a la Edad forma Neovascular”. Protocolo nº OPH 1001

C. Vitae Jordi Monés 11

7.24.

2010 – Completed: Principal investigator principal & co-designer

protocol – An open-label investigator research grant trial to establish the safety of intravitreous injections of E10030 (ANTI-PDGF aptamer) given in combination with Lucentis® in subjects with neovascular age-related macular degeneration. Protocol E10030-001. 7.25.

2011 – Ongoing: Principal Investigator. Pilot phase II clinical trial to

evaluate the safety of human fetal retinal transplant in the treatment of geographic secondary to age-related macular degeneration and retinitis pigmentosa. Institut de la Màcula i de la Retina, Barcelona Macula Foundation. 7.26.

2011- Ongoing: Principal Investigator and Steering committee member

Crystal: A 24-month, phase IIIb, open-label, single arm, multicenter study assessing the efficacy and safety of individualized, stabilization criteria-driven pro re rata (PRN) dosing regimen with 0.5-mg ranibizumab intravitreal injections applied as monotherapy to patients with visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO). Promotor: Novartis. Institut de la Màcula i de la Retina, Barcelona Macula Foundation. 7.27.

2011- Ongoing: Principal Investigator and Steering committee member

Brighter: A 24-month, phase IIIb, randomized, active-controlled, three-arm, multicenter study assessing the efficacy and safety of an individualized, stabilization criteria driven PRN dosing regimen with 0.5 mg ranibizumab intravitreal injections applied as monotherapy or with adjunctive laser photocoagulation in comparison to laser photocoagulation in patients with visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO). Promotor: Novartis. Institut de la Màcula i de la Retina, Barcelona Macula Foundation. 7.28.

2013 - Ongoing: Principal Investigator. A phase II randomized, double-

mask study to establish the safety and efficacy of high-dose oral Omega 3 in subjects with high-risk drusen secondary to dry age-related macular

C. Vitae Jordi Monés 12

degeneration. Institut de la Màcula i de la Retina, Barcelona Macula Foundation. 7.29.

2013 – Ongoing: Principal Investigator. A phase II randomized, double-

mask study to establish the safety and efficacy of high-dose oral Omega 3 in subjects with geographic secondary to dry age-related macular degeneration. Institut de la Màcula i de la Retina, Barcelona Macula Foundation. 7.30.

2012 - Ongoing: Principal Investigator, The geographic atrophy in pig

study (the gap study): A phase I escalating dose of subretinal sodium iodate: a toxic-induced animal model of geographic atrophy of RPE and photoreceptors. Institut de la Màcula i de la Retina, Barcelona Macula Foundation 7.31.

2012 - Ongoing: Principal Investigator, The MPL4 Drusen Study. a

phase I study to establish the safety and efficacy of retinal pigment epithelium Micropulse Laser in subjects with high-risk drusen secondary to age-related macular degeneration. Institut de la Màcula i de la Retina, Barcelona Macula Foundation 7.32.

2012- Ongoing: Principal Investigator, The MPL4 Dry Study. A phase I

study to establish the safety and efficacy of retinal pigment epithelium Micropulse Laser in subjects with geographic atrophy secondary to dry agerelated macular degeneration. Institut de la Màcula i de la Retina, Barcelona Macula Foundation 7.33.

2011 – Ongoing: Principal Investigator. Translational Research in

regenerative stem cell therapies for retinal degenrative diseases from the swine animal model of retinal atrophy to clinical trials in human patients with age-related macular degeneration, retinitis pigmentosa and Stargardt’s disease. Barcelona Macula Foundation; Center of regenerative Medicine in Barcelona, Universitat Autònoma de Barcelona. 7.34.

2013- 2016: Principal investigator in Catalonia Site. LITE: Laser

imaging Techniques for the anterior and posterior eye. Institut de Ciències

C. Vitae Jordi Monés 13

Fotòniques; Istituto Nazionale di Ottica; Istituto di Fisica Applicata Nello Carrara, Construzione Strumenti Oftalmici and Institut de la Màcula i de la Retina. ERANET Biophotonics. European Comission Financed. 7.35.

2013- 2015. Principal Investigator. Study Macbeth. Ensayo Clínico fase

IV para evaluar la eficacia de Aflibercept en pacientes con degenración mcular ascoiada a la edad (DMAE) neovascular, sin respuesta óptima a repetidas inyecciones mensuales intravitreas de anti VEGFA. Promotor: Bayer. 7.36.

2014- Ongoing: Principal investigator. Eclipse. A phase 3 Randomized,

doubled masked, controlled trial to establish the safety and efficay of intravitreous administrarion of FOVISTA (anti-PDGF-b pegylated aptamer) administered in combination with Lucentis compared to Lucentis Monotherapy in subjects with suffoveal neovascular age-related macular degeneration. Multicenter clinical trial. Promotor:Ophthtech Parexel. 7.37.

2014- Ongoing: Principal Investigator. In Eye- Study. Ensayo Clínico en

fase IV, abiero, aleatorizado, de 3 brazos, multicéntrico y de 12 meses de duración, para evaluar la eficacia y seguridad de dos régimenes de tratamiento, bimensual o PRN flexible individualizado de “tratar y extender”, versus un régimen PRN según citerios de establización mediante evaluaciones mensuales de inyecciones intravítreas de Ranibizumab 0.5mg en pacientes naive con neovascularización coroidea secundaria a la DMAE. Promotor: SERV. 7.38.

2014- 2015: Principal Investigator. Trend Study. Estudio fase IIIB

multicentrico, randommizado, de 12 meses de seguimiento con evaluador de la agudeza visual enmascarado para evaluar la eficacia y la seguridad de Ranibizumab 0.5mg en un régimen de tratar y extender comparado con un régimen mensual, en pacientes con degeneración mcular neoovascular asociada a la edad. Promotor: Novartis.

C. Vitae Jordi Monés 14

7.39.

2014- Ongoing: Principal Investigator. Assessment of anatomical and

functional outcomes in patients treated with ocriplasmin for vitreomacular traction/symptomatic vitreomacular adhesion. Multicenter trial. Promotor: Alcon. 7.40.

2014- Ongoing: Principal Investigator. Study

MegaOmega4Dry. A

phase II randomized, double-mask study to establish the safety and efficacy of High-dose oral Omega 3 in subjects with macular degeneration. Institut de la Màcula i de la Retina, Barcelona Macula Foundation. 7.41.

2015-Ongoing: Innovative PROcurement for Visually Impaired People

(PRO4VIP). European Pre-Commercial Public Procurement (PCP) and Innovative Public Procurement (IPP) project that forms part of the European Vision 2020 strategy. Coordinated by AQuAS (Generalitat de Catalunya), it enjoys the participation of the Barcelona Macula Foundation, together with 12 other institutions from England, the rest of Spain, Denmark, France and Italy. 7.42.

2015-Ongoing: Exploring the combined role of genetic and non-genetic

factors for developing Age-Related Macular Degeneration: A systems level analysis of disease subgroups, risk factors, and pathways (EYE-RISK). Topic PHC-01-2014. Horizon 2020. Coordinated by Eberhard Karls Universitaet Tuebingen (EKUT), it enjoys the participation of the Barcelona Macula Foundation, together with 10 other institutions. 7.43.

2015-Ongoing: DARK. Deterioration of the Dark adaptation function in

patients with drusen. Estudio Observacional Transversal. Institut De La Màcula and Barcelona Macula Foundation. 7.44.

2015-Ongoing: HARRIER (RTH258–C002). Estudi fase III, multicèntric,

randomitzat, amb doble emmascarament de dos anys de durada que pretén avaluar l’eficàcia i la seguretat de RTH258 6 mg en comparació amb aflibercept (EYLEA) en subjectes amb DMAE exsudativa.

C. Vitae Jordi Monés 15

7.45.

Financial requested: iPSC: A potential candidate for the regeneration of

retinal pigment epithelium for retinal degenerative diseases. Barcelona Macula Foundation (BMF) and Fundación Leitat. 7.46.

Financial requested: TopGene. Topical gene delivery for Retinal

Degenerative Diseases based on smart non-viral vectors. Barcelona Macula Foundation (BMF), Universidad Miguel Hernandez (UMH), CIBER-BBN. 7.47.

Financial requested: CORTIVIS approach for an Intracortical Visual

Prostheses. Barcelona Macula Foundation (BMF), Universidad Miguel Hernandez (UMH) I Fundación LEITAT. 7.48.

Financial requested: OPTO4EYE. Visual Restoration for Retinal

Dystrophies using Optogenetics: Transaltional Research. Barcelona Macula Foundation; University Miguel Hérnandez (UMH) and University Basque Country (UPV/EHU). 7.49.

To be started: ADVANCE.CAT. Accelerating Development

ON

Advanced Teraphies in Catalonia. RIS3CAT communities. The research and innovation strategy of Catalonia. Generalitat de Catalunya. Financed by FEDER source.

8. SCIENTIFIC PUBLICATIONS: 8.1. Editor/Author Book: 8.1.1. Degeneración Macular Asociada a la Edad. J Monés, F Gómez Ulla (eds) Barcelona, Prous Science, 2005. 8.2. Autor Book Chapters: 8.2.1. Monés i Carilla J, Friedman E: Angiografia coroidea con indocianina verde en la degeneración macular asociada con la edad. In: La Mácula Senil. Gómez-Ulla F (ed). Ciba Visión, Barcelona, 5: 75, 1993.

C. Vitae Jordi Monés 16

8.2.2. Monés JM, Guyer DR, Puliafito CP:

Indocyanine green angiography.

In: Principles and Practice of Ophthalmology. Albert DM, Jakobiec FA (eds). Philadelphia, WB Saunders, (2) 52: 718, 1994. 8.2.3. Monés i Carilla J: Videoangiografía con indocianina verde mediante Scanning Laser Ophthalmoscope: Generalidades. In: Nuevos Métodos de Exploración retiniana. Gómez-Ulla F (ed). Sociedad Española de Oftalmología, Madrid, 3: 37, 1994. 8.2.4. Monés i Carilla J: Videoangiografía con indocianina verde mediante Scanning Laser Ophthalmoscope en la DMAE. In: Nuevos Métodos de Exploración retiniana.

Gómez-Ulla F (ed).

Sociedad Española de

Oftalmología, Madrid, 6: 67, 1994. 8.2.5. Monés JM, Slakter J: Indocyanine Videoangiography in Serpiginous Choroidopathy. IN:

Indocyanine Green Angiography.

Yannuzzi LA,

Flowe RW, Slakter JS. St. Louis, Mosby, (17): 247, 1997. 8.2.6. Monés JM. Luxación posterior de lentes intraoculares. In: Corcóstegui B (Eds) Sociedad Española de Oftalmología. Torremolinos, September 1999 8.2.7. Monés JM, Guyer DR, Puliafito CP:

Indocyanine green angiography.

In: Principles and Practice of Ophthalmology. 2nd edition

Albert DM,

Jakobiec FA (eds). Philadelphia, WB Saunders, (2) 52: 718, 1999. 8.2.8. Monés JM. PDT for miopía. In: Photodynamic Therapy of Ocular Diseases.

Gragoudas ES, Miller JW, Zografos L (eds).

Lippincot,

Williams & Wilkins. Philadelplhia 8.2.9. Monés JM, Loewenstein A. Perimetría de Hiperagudeza Preferencial. In: Degeneración Macular Asociada a la Edad. J Monés, F Gómez Ulla (eds) Barcelona, Prous Science, 2005.

C. Vitae Jordi Monés 17

8.2.10.

Arias L, Monés JM. Terapia Fotodinámica em DMAE. In:

Degeneración Macular Asociada a la Edad. J Monés, F Gómez Ulla (eds) Barcelona, Prous Science, 2005. 8.2.11.

Mateo C, Pérez Belmonte L, Navarro R, Monés J. Translocación

macular. In: Degeneración Macular Asociada a la Edad. J Monés, F Gómez Ulla (eds) Barcelona, Prous Science, 2005. 8.2.12.

Monés JM, Guyer DR, Puliafito CP. Indocyanine green

angiography. In: Principles and Practice of Ophthalmology. Albert DM, Jakobiec FA (eds). 2nd edition Philadelphia, WB Saunders, 2007 8.2.13.

Fundus autofluorescence

patterns

and optical coherence

tomography in geographic atrophy secondary to AMD"AMD. Revision book". Silva R et al. Ed Théa, 2010 (at the publisher) 8.2.14.

Jonas J, Paques M, Monés J, Glacet-Bernard A. Retinal Vein

Occlusion. Macular Edema. Ed. Gab riel Coscas (at the publisher) 8.2.15.

Loewenstein A, Zur D, Tufail A, Monés J. Postsurgical cystoid

macular edema. Retinal Vein Occlusion. Macular Edema. Ed. Gabriel Coscas (at the publisher)

8.3. Spanish Scientific Journals: 8.3.1. Vilaplana i Blanch D, Soler i Tomàs JR, Monés i Carilla JM, Sena i Dutrenit JM. Profilaxis del desprendimiento de la retina. Fotocoagulación con làser. Revista d'Or d'Oftalmologia, 1988. 8.3.2. Soler i Tomàs JR, Vilaplana i Blanch D, Monés i Carilla JM, Sena i Dutrenit JM. Estudio comparativo làser Argon versus Krypton rojo en el tratamiento de la coroidorretinopatía central serosa. Revista d'Or d'Oftalmologia, 1989.

C. Vitae Jordi Monés 18

8.4. International Scientific Journals: 8.4.1. Monés JM, Woods WJ, Puliafito CA. Retinal toxicity of hyaluronidase and thimerosal injected into the vitreous body of the rabbit.

Invest

Ophthalmol Vis Sci 32 (4) (Suppl): 879, 1991. 8.4.2. Bauman WC, Monés JM, Tritten JJ, Lin CP, Gragoudas E, Puliafito CA. Transpupillary phthalocyanine photodynamic therapy of experimental posterior malignant melanoma. Invest Ophthalmol Vis Sci 32 (4) (Suppl): 713, 1991. 8.4.3. Puliafito CA, Guyer DR, Monés JM, Weaver Y.

Indocyanine-Green

Digital Angiography and Dye-Enhanced Diode Laser Photocoagulation of Choroidal Neovascularization. Invest Ophthalmol Vis Sci 32 (4) (Suppl): 712, 1991. 8.4.4. Guyer DR, Puliafito CA, Monés JM, et al. Indocyanine-green digital angiography in chorioretinal disorders. Ophthalmol 99: 287, 1992. 8.4.5. Corcóstegui B, Monés JM. Indocyanine videangiography with Scanning Laser Ophthalmoscope of large choroidal vessels in exudative agerelated macular degeneration. Invest Ophthalmol Vis Sci 35 (4) (Suppl): 1507, 1994. 8.4.6. Monés J and the VIP Study Group. Photodynamic therapy (PDT) with Verteporfin of subfoveal choroidal neovascularization in age-related macular degeneration: Study design and baseline characteristics in the VIP randomized clinical trial. Invest Ophthalmol Vis Sci 40 (4) (Suppl): 1703 1999. 8.4.7. TAP Study Group (Jordi Monés is the writing Committee). Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study

Group:

Neovascularization

Photodynamic in

Therapy

Age-Related

of

Macular

Subfoveal

Choroidal

Degeneration

with

Verteporfin. One-Year Results of 2 Randomized Clinical Trials – TAP

C. Vitae Jordi Monés 19

Report 1. Arch Ophthalmol 1999; 117: 1329 – 1345. 8.4.8. TAP Study Group (Jordi Monés as is the writing Committee).

Case

series of VA improvements following PDT with Verteporfin fon CNV in AMD (In preparation) 8.4.9. TAP Study Group (Jordi Monés as is the writing Committee). Photodynamic therapy of subfoveal choroidal neovascularization in agerelated macular degeneration with verteporfin: two-year results of 2 randomized

clinical

trials-tap

report

2.

Arch

Ophthalmol

2001

Feb;119(2):198-207. 8.4.10.

VIP Study Group (Jordi Monés as is the writing Committee).

Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Pathologic Myopia with Verteporfin. Randomized Clinical Trials.

Two-year Vision Results of 2

VIP report 1. Ophthalmology 2001

May;108(5):841-852 8.4.11.

VIP Study Group (Jordi Monés as is the writing Committee).

Verteporfin Therapy of Subfoveal choroidal neovascularization in agerelated macular degeneration: two-year results of a randomised clinical trial

including

lesions

with

occult

with

no

classic

choroidal

neovascularization – verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001 May, 131 (5): 541-560. 8.4.12.

Verteporfin Roundtable 2000 and 2001 Participants; Treatment

of age-related macular degeneration with photodynamic therapy (TAP) study group principal investigators; Verteporfin in photodynamic therapy (VIP) study group principal investigators. Guidelines for using verteporfin (visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina. 2002 Feb;22(1):6-18.

C. Vitae Jordi Monés 20

8.4.13.

VIP Study Group (Jordi Monés as is the writing Committee).

Letter to the Editor of the American Journal of Ophthalmology regarding additional data relevant to VIP Report 2. 8.4.14.

Blumenkranz MS, Bressler NM, Bressler SB, Donati G, Fish GE,

Haynes LA, Lewis H, Miller JW, Mones JM, Potter MJ, Pournaras C, Reaves A, Rosenfeld PJ, Schachat AP, Schmidt-Erfurth U, Sickenburg M, Singerman LJ, Slakter JS, Strong A, Vannier S; Treatment of AgeRelated Macular Degeneration with Photodynamic Therapy (TAP) Study Group.Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials--TAP Report no. 5. Arch Ophthalmol. 2002 Oct;120(10):1307-14. 8.4.15.

Bressler NM, Arnold J, Benchaboune M, Blumenkranz MS, Fish

GE, Gragoudas ES, Lewis H, Schmidt-Erfurth U, Slakter JS, Bressler SB, Manos K, Hao Y, Hayes L, Koester J, Reaves A, Strong HA; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study

Group.

Verteporfin

therapy

of

subfoveal

choroidal

neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision

outcomes-TAP

report

No.

3.

Arch

Ophthalmol.

2002

Nov;120(11):1443-54 8.4.16.

Barbazetto I, Burdan A, Bressler NM, Bressler SB, Haynes L,

Kapetanios AD, Lukas J, Olsen K, Potter M, Reaves A, Rosenfeld P, Schachat AP, Strong HA, Wenkenstern A; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study Group; Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment--TAP and VIP report No. 2. Arch Ophthalmol. 2003 Sep;121(9):1253-68

C. Vitae Jordi Monés 21

8.4.17.

Blinder KJ, Blumenkranz MS, Bressler NM, Bressler SB, Donato

G, Lewis H, Lim JI, Menchini U, Miller JW, Monés JM, Potter MJ, Pournaras C, Reaves A, Rosenfeld P, Schachat AP, Schmidt-Erfurth U, Sickenberg M, Singerman LJ, Slakter JS, Strong HA, Virgili G, Williams GA. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial-VIP report no. 3. Ophthalmology. 2003 Apr;110(4):667-73. 8.4.18.

TAP Study Group (Jordi Monés as is the writing Committee).

Blinder KJ, Bradley S, Bressler NM, Bressler SB, Donati G, Hao Y, Ma C, Menchini U, Miller J, Potter MJ, Pournaras C, Reaves A, Rosenfeld PJ, Strong HA, Stur M, Su XY, Virgili G; Treatment of Age-related Macular Degeneration with Photodynamic Therapy study group; Verteporfin in Photodynamic Therapy study group. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to agerelated macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol. 2003 Sep;136(3):407-18 8.4.19.

Azab M, Benchaboune M, Blinder KJ, Bressler NM, Bressler SB,

Gragoudas ES, Fish GE, Hao Y, Haynes L, Lim JI, Menchini U, Miller JW, Monés J, Potter MJ, Reaves A, Rosenfeld PJ, Strong A, Su XY, Slakter JS, Schmidt-Erfurth U, Sorenson JA; Treatment of Age-Related Macular Degeneration

with

Photodynamic

Therapy

(TAP)

Study

Group;

Verteporfin in Photodynamic Therapy (VIP) Study GroupVerteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment Of Age-Related Macular Degeneration With Photodynamic Therapy and Verteporfin In Photodynamic Therapy Study. Report no. 4. Retina. 2004 Feb;24(1):1-12.

C. Vitae Jordi Monés 22

8.4.20.

(Jordi Monés as in the Writing Committee). Pegaptanib for

Neovascular

Age-Related

Macular

Degeneration.

Evangelos

S.

Gragoudas, M.D., Anthony P. Adamis, M.D.,Emmett T. Cunningham, Jr., M.D., Ph.D., M.P.H., Matthew Feinsod, M.D.,and David R. Guyer, M.D., for the VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. n engl j med 351;27 www.nejm.org December 30, 2004 8.4.21.

Monés J, Rubin GS. Contrast sensitivity as an outcome

measure in patients with subfoveal choroidal neovascularisation due to age-related macular degeneration. Eye (Lond). 2005 Nov;19(11):1142-50. Review. 8.4.22.

TAP Study Group (Jordi Monés as in the writing Committee).

Verteporfin Therapy for Subfoveal Choroidal Neovascularization in AgeRelated Macular Degeneration: Four-Year Results of an Open-Label Extension of 2 Randomized Clinical Trials: TAP Report No. 7 Arch Ophthalmol. 2005;123:1283-1285. 8.4.23.

Chakravarthy U, Soubrane G, Bandello F, Chong V, Creuzot-

Garcher C, Dimitrakos SA 2nd, Korobelnik JF, Larsen M, Monés J, Pauleikhoff D, PournarasCJ, Staurenghi G, Virgili G, Wolf S. Evolving European guidance on the medical management of neovascular age related macular degeneration.Br J Ophthalmol. 2006 Sep;90(9):1188-96. 8.4.24.

Monés J. New perspectives on the treatment of age-related

macular degeneration. Drugs Today (Barc). 2005 Nov;41(11):701. 8.4.25.

Monés JM, Lopez MA, Prieto JA, Rodriguez JP.Extrafoveal

choroidal neovascularization secondary to wet age-related macular degeneration treated with intravitreal bevacizumab.Ophthalmic Surg Lasers Imaging. 2007 May-Jun;38(3):226-8. 8.4.26.

Monés J [Bevacizumab or Ranibizumab, or the tale of Robin

Hood and King Richard Lion Heart.]Arch Soc Esp Oftalmol. 2007 Sep;82(9):529-30. Spanish. No abstract available. PMID: 17846939

C. Vitae Jordi Monés 23

[PubMed - in process] 8.4.27.

Soubrane G, Cruess A, Lotery A, Pauleikhoff D, Monés J, Xu X,

Zlateva G, Buggage R, Conlon J, Goss TF. Burden and health care resource utilization in neovascular age-related macular degeneration: findings of a multicountry study. Arch Ophthalmol. 2007 Sep;125(9):124954. 8.4.28.

Cruess AF, Zlateva G, Xu X, Soubrane G, Pauleikhoff D, Lotery

A, Monés J, Buggage R, Schaefer C, Knight T, Goss TF. Economic burden of bilateral neovascular age-related macular degeneration: multicountry observational study. Pharmacoeconomics. 2008;26(1):57-73. 8.4.29.

Monés J, Amselem L, Serrano A, García M, Hijano M.

Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia: 12-month results. Eye. 2009 Jun;23(6):1275-80 8.4.30.

Amselem L, Pulido JS, Gunduz K, García-Arumí J, Monés J.

Infrared reflectance in choroidal melanomas and its correlation with fundus autofluorescence.

Br J Ophthalmol. 2008 Nov;92(11):1565-6.

[Pubmed] 8.4.31.

Ruiz-Moreno

JM,

Arias-Barquet

L,

Armadá-Maresca

F,

Boixadera-Espax A, García-Layana A, Gómez-Ulla-de-Irazazábal F, Monés-Carilla

J,

Piñero-Bustamante

A,

Suárez-de-Figueroa

M.

[Guidelines of clinical practice of the SERV: treatment of exudative agerelated macular degeneration (AMD)] Arch Soc Esp Oftalmol. 2009 Jul;84(7):333-44. 8.4.32.

Arias L. Monés J. Transconjunctival sutureless vitrectomy with

tissue plasminogen activator, gas and intravitreal bevacizumab in the management

of

predominantly

hemorrhagic

age-related

macular

degeneration. Clinical Ophthalmology 2010: 4 67-72 8.4.33.

Arias L, Monés J. Ranibizumab in the treatment of choroidal

C. Vitae Jordi Monés 24

neovascularization on the border of an inferior staphyloma associated with tilted disc syndrome. Clin Ophthalmol. 2010 Apr 26;4:227-31. 8.4.34.

Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M,

Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM; OZURDEX GENEVA Study Group. ( Jordi Monés as in the GENEVA Study Group). Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010 Jun;117(6):1134-1146.e3. Epub 2010 Apr 24 8.4.35.

Jonas J, Paques M, Monés J, Glacet-Bernard A. Retinal vein

occlusions. Dev Ophthalmol. 2010;47:111-35. Epub 2010 Aug 10. Review. 8.4.36.

Biarnés M, Monés J, Villalbí JR, Arias L. As-needed treatment

with ranibizumab 0.5 mg in patients with neovascular age-related macular degeneration. Eur J Ophthalmol. 2011 May-Jun;21(3):282-9. doi: 10.5301/EJO.2010.5766. PMID: 20890885 [PubMed - indexed for MEDLINE] 8.4.37.

Monés J. A Review of Ranibizumab Clinical Trial Data in

Exudative Age-Related Macular Degeneration and How to Translate It into

Daily

Practice.

Ophthalmologica.

2011;225(2):112-9.

doi:

10.1159/000319906. Epub 2010 Oct 8. 8.4.38.

Zur D, Fischer N, Tufail A, Monés J, Loewenstein A.Postsurgical

cystoid macular edema. Eur J Ophthalmol. 2011;21 Suppl 6:S62-8. doi: 10.5301/EJO.2010.6058. 8.4.39.

Biarnés M, Monés J, Arias L, Villalbí JR. An Update on

Geographic Atrophy in Age-Related Macular Degeneration Optometry and Vision Science. Optometry and Vision Science. Optom Vis Sci. 2011 Apr 28. [Epub ahead of print]

C. Vitae Jordi Monés 25

8.4.40.

Coscas G, Loewenstein A, Augustin A, Bandello F, Battaglia M,

Lanzetta P, Monés J, de Smet M, Soubrane G, Staurenghi G. Management of Retinal Vein Occlusion – Consensus Document. Ophthalmologica 2011;226:4-28. 8.4.41.

Biarnés M, Monés J, Trindade F, Alonso J, Arias L. Intra and

interobserver agreement in the classification of fundus autofluorescence patterns in geographic atrophy secondary to age-related macular degeneration Graefes Arch Clin Exp Ophthalmol. 2012 Apr;250(4):48590. Epub 2011 Oct 28. 8.4.42.

Monés J, Biarnés M, Trindade F. Hyporeflective wedge-shaped band

in geographic atrophy secondary to age-related macular degeneration: an underreported finding. Ophthalmology. 2012 Jul;119(7):1412-9. Epub 2012 Mar 21. 8.4.43.

Monés J, Biarnés M, Trindade F, Casaroli-Marano R. FUSION

regimen: ranibizumab in treatment-naïve patients with exudative agerelated macular degeneration and relatively good baseline visual acuity. Graefes Arch Clin Exp Ophthalmol. 2012 Dec;250(12):1737-44. Epub 2012 Apr 15. 8.4.44.

Monés J, Biarnés M, Trindade F, Arias L, Alonso J. Optical

Coherence Tomography Assessment of Apparent Foveal Swelling in Ophthalmology. 2013 Apr;120(4):829-36. doi: 10.1016/j.ophtha.2012. 09.054. Epub 2013 Jan 3. 8.4.45.

L. Arias Barquet and J. Monés. New treatment protocols and

follow-up in patients with exudative age-related macular degeneration. Archivos de la Sociedad Española de Oftalmología. Volume 87. Supplement 1. December 2012. 8.4.46.

Lanzetta P. Holz F. Monés J. Querques G. Stanga P. Veritti D.

Barbone F. Brusaferro S. Isola M. Intravitreal Injections: A Healthcare

C. Vitae Jordi Monés 26

Failure

Modes

and

Effects

Analysis.

Ophthalmologica

(DOI:

10.1159/000354549). 8.4.47.

Monés J, Biarnés M, Badal J. Bimonthly half-dose ranibizumab

in large pigment epithelial detachment and retinal angiomatous proliferation with high risk of retinal pigment epithelium tear: a case report. Clin Ophthalmol. 2013;7:1089-92. doi: 10.2147/OPTH.S45155. Epub 2013 Jun 7. 8.4.48.

Monés J. as a participant of a round table of participant leaders.

Advocating for Improved treatment and Outcomes for Wet Age-retaled Macular Degeneration. A report based on an International Expert Summit. Convened in Berlin, Germany November 2011. The Angiogenesis Foundation. 8.4.49.

Alfredo García-Layana, Luis Arias, Marta S. Figueroa, Monés J.

Araiz, José María Ruiz-Moreno, José Garcia-Aruní, Francisco GómezUlla, María Isabel López-Gálvez, Francisco Cabrera-López, José Manuel García Campos, Jordi Monés, Enrique Cervera, Félix Armadá, Miguel Ángle Serrano, Juan Donate, Roberto Gallego-Pinazo. Guía clínica de Expertos sobre el Manejo de la Degeneración Macular Asociada a la Edad Exudativa. Revista Española de Patología Macular. Volumen IV. Nº4. Noviembre de 2013. 8.4.50.

Ursula Schmidt-Erfurth, Victor Chong, Anat Loewenstein,

Michael Larsen, Eric Souied, Reinier Schlingemann, Bora Eldem, Jordi Monés, Gisbert Richard and Francesco Bandello.

“Guidelines for the

management of neovascular age-related macular degeneration” by the European Society of Retina Specialists (EURETINA). The British journal of ophthalmology 09/2014; 98(9):1144-1167. DOI: 10.1136/bjophthalmol2014-305702 8.4.51.

Biarnés M, Forero CG, Arias L, Alonso J, Monés J. Reappraisal

of geographic atrophy patterns seen on fundus autofluorescence using a

C. Vitae Jordi Monés 27

latent class analysis approach. Invest Ophthalmol Vis Sci. 2014 Nov 18. pii: IOVS-13-13542. doi: 10.1167/iovs.13-13542. [Epub ahead of print].

8.4.52.

Cunha-Vaz J, Ashton P, Iezzi R, Campochiaro P, Dugel PU,

Holz FG, Weber M, Danis RP, Kuppermann BD, Bailey C, Billman K, Kapik B, Kane F, Green K; FAME Study Group. Monés J. as a collborator. Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edema. Ophthalmology.

2014

Oct;121(10):1892-903.

doi:

10.1016/j.ophtha.2014.04.019. Epub 2014 Jun 14.

8.4.53.

Boyer DS, Goldbaum M, Leys AM, Starita C; V.I.S.I.O.N. Study

Group. Monés J as a collaborator. Effect of pegaptanib sodium 0.3 mg intravitreal injections (Macugen) in intraocular pressure: posthoc analysis from V.I.S.I.O.N. study. Br J Ophthalmol. 2014 Nov;98(11):1543-6. doi: 10.1136/bjophthalmol-2013-304075. Epub 2014 Jul 4.

8.4.54.

Gerding H, Monés J, Tadayoni R, Boscia F, Pearce I, Priglinger

S. Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel. Br J Ophthalmol. 2014 Jul 29. pii: bjophthalmol-2014305041. doi: 10.1136/bjophthalmol-2014-305041. [Epub ahead of print]

8.4.55.

García-Layana A, Arias L, Figueroa MS, Araiz J, Ruiz-Moreno

JM, García-Arumí J, Gómez-Ulla F, López-Gálvez MI, Cabrera-López F, García-Campos JM, Monés J, Cervera E, Armadá F, Gallego-Pinazo R, Piñero-Bustamante A, Serrano-Garcia M. A delphi study to detect deficiencies and propose actions in real life treatment of neovascular agerelated macular degeneration. J Ophthalmol. 2014;2014:595132. doi: 10.1155/2014/595132. Epub 2014 Dec 21.

8.4.56.

Biarnés M, Arias L, Alonso J, Garcia M, Hijano M, Rodríguez A,

C. Vitae Jordi Monés 28

Serrano A, Badal J, Muhtaseb H, Verdaguer P, Monés J. Increased Fundus Autofluorescence and Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration: The GAIN Study. Am J Ophthalmol. 2015 Aug;160(2):345-353.e5. doi:10.1016/j.ajo.2015.05.009. Epub 2015 May 15. PMID: 25982972 8.4.57.

Freund KB, Korobelnik JF, Devenyi R, Framme C, Galic J,

Herbert E, Hoerauf H, Lanzetta P, Michels S, Mitchell P, Monés J, Regillo C, Tadayoni R, Talks J, Wolf S. Treat-And-Extend Regimens With AntiVegf Agents in Retinal Diseases: A Literature Review and Consensus Recommendations. Retina. 2015 Jun 12. [Epub ahead of print]

8.4.58.

Dr. Jordi Monés, Dr. Josep Badal, Dr. Marc Biarnés. Feeder

Vessel Laser Photocoagulation For Idiopathic, Subfoveal Polypoidal Choroidal Vasculopathy Not Responding To Either Anti-Vascular Endothelial Growth Factor Therapy Or Photodynamic Therapy. Retin Cases

Brief

Rep.

2016

Winter;10(1):100-3.

doi:

10.1097/ICB.0000000000000174.

8.4.59.

Richard G, Monés J, Wolf S, Korobelnik JF, Guymer R,

Goldstein M, Norenberg C, Sandbrink R, Zeitz O. Scheduled versus Pro Re

Nata

Dosing

in

the

VIEW

Trials.

Ophthalmology.

2015

Dec;122(12):2497-503. doi: 10.1016/j.ophtha.2015.08.014. Epub 2015 Oct 21. PMID: 26477840 8.4.60.

Alfredo García-Layana, Marta S. Figueroa, Luis Arias, Javier

Araiz, José María Ruiz-Moreno, José García-Arumí, Francisco GómezUlla, María Isabel López-Gálvez, Francisco Cabrera-López, José Manuel García-Campos, Jordi Monés, Enrique Cervera, Felix Armadá, and Roberto Gallego-Pinazo. Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration. Journal of Ophthalmology, vol. 2015, Article ID 412903, 8 pages, 2015. doi:10.1155/2015/412903.

C. Vitae Jordi Monés 29

8.4.61.

Larsen M, Waldstein SM, Boscia F, Gerding H, Monés J,

Tadayoni R, Priglinger S, Wenzel A, Barnes E, Pilz S, Stubbings W, Pearce I; CRYSTAL Study Group. Individualized Ranibizumab Regimen Driven by Stabilization Criteria for Central Retinal Vein Occlusion: Twelve-Month Results of the CRYSTAL Study. Ophthalmology. 2016 May;123(5):1101-11. doi: 10.1016/j.ophtha.2016.01.011. Epub 2016 Feb 17. 8.4.62.

Monés

Mar;36(3):e20.

J, doi:

Biarnés

M.

Correspondence.

10.1097/IAE.0000000000000944.

Retina. No

2016

abstract

available. 8.4.63.

Marc Biarnés, PhD; Jordi Monés, MD, PhD. Direct Visualization

of a New Choroidal Vessel on Spectral-Domain Optical Coherence Tomography. Ophthalmic Images | March 10, 2016. JAMA Ophthalmol. 2016;134(3):e155017. doi:10.1001/jamaophthalmol.2015.5017. 8.4.64.

Tadayoni R, Waldstein SM, Boscia F, Gerding H, Pearce I,

Priglinger S, Wenzel A, Barnes E, Gekkieva M, Pilz S, Monés J; BRIGHTER study group. Individualized Stabilization Criteria-Driven Ranibizumab versus Laser in Branch Retinal Vein Occlusion: Six-Month Results of BRIGHTER. Ophthalmology. 2016 Jun;123(6):1332-44. doi: 10.1016/j.ophtha.2016.02.030. Epub 2016 Mar 30.

9. SCIENTIFIC PRESENTATIONS: 9.1.

Spanish Meetings:

9.1.1. Monés i Carilla JM, Ruiz Bulumar JL.: "Uso de la Mezlocilina tópica en el Tratamiento del Absceso Corneal por Pseudomonas". CONGRESO

NACIONAL

DE

LA

SOCIEDAD

ESPAÑOLA

"LXIII DE

OFTALMOLOGIA". Oviedo, September 1987. 9.1.2. Monés JM: "Lesiones predisponentes. Profilaxis del desprendimiento

C. Vitae Jordi Monés 30

de la retina". "III CURSO DEL DESPRENDIMIENTO DE RETINA Y VITREO. INSTITUTO CASTANERA". Barcelona, October 1987. 9.1.3. Monés i Carilla JM, Rodriguez i Prats JL, Iglesias i Touriño E: "Afectació Ocular en la Neurofibromatosi de Von Reckinghausen". "VII JORNADES MÈDIQUES DEL VALLÈS.

ACADÈMIA DE CIÈNCIES

MÈDIQUES DE CATALUNYA I BALEARS". Sabadell, November 1987. 9.1.4. Monés i Carilla JM, Soler i Tomàs JR, Iglesias i Touriño E: "Tractament de l'Abscés Cornial Bacterià Resistent als Antibiòtics Convencionals". "VII JORNADES MÈDIQUES DEL VALLÈS.

ACADÈMIA DE

CIÈNCIES MÈDIQUES DE CATALUNYA I BALEARS".

Sabadell,

November 1987. 9.1.5. Vilaplana i Blanch D, Soler i Tomàs JR, Monés i Carilla JM, Sena i Dutrenit JM: "Fotocoagulació Làser en la Profilaxi del Desprendiment de la Retina". "VII JORNADES MÈDIQUES DEL VALLÈS. ACADÈMIA DE CIÈNCIES MÈDIQUES DE CATALUNYA I BALEARS". Sabadell, November 1987. 9.1.6. Monés i Carilla, JM, Samaan M:

"Goniotomía ab interno y

trabeculotomía ab externo con trabeculectomía". "LXIV CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGIA". Palma de Mallorca, October 1988. 9.1.7. Monés J, Corcóstegui B: "Videoangiografia amb indocianina verda oftalmoscopi de làser d'scanning (VICV - SLO) en la degeneració macular associada a l'edat (DMAE) forma exudativa."

"NOVES

TÉCNIQUES D'EXPLORACIÓ I DIAGNÒSTIC EN OFTALMOLOGIA". La Seu D'Urgell, April 1994. 9.1.8. Monés J, Corcóstegui B: " Videoangiografia amb indocianina verda oftalmoscopi de làser d'scanning (VICV - SLO). Estudi i diagnòstic de les

malalties

inflamatòries

coroidals."

"NOVES

TÉCNIQUES

D'EXPLORACIÓ I DIAGNÒSTIC EN OFTALMOLOGIA".

La Seu

C. Vitae Jordi Monés 31

D'Urgell, April 1994. 9.1.9. Monés J, García Arumí J, Adán A:

"Estudio y diagnóstico de las

coroiditis mediante la videongiografía indocianina verde - SLO." "LXX CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA". Tenerife, September 1994. 9.1.10.

Monés J, Mateo C, Corcóstegui B: "Detección y clasificación de

las membranas neovasculares coroideas en la DMAE mediante videoangiografía ICV - SLO. "LXX CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA". Tenerife, September 1994. 9.1.11.

Monés J, Corcóstegui B, Durán N:

coroideos submaculares en la DMAE."

"Patrones cicrculatorios

"LXX CONGRESO DE LA

SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA". Tenerife, September 1994. 9.1.12.

Monés

J,

Corcóstegui

B:

"Efecte

a

distància

de

la

fotocoagulació amb làser de diode: una complicació o una estratègia terapeútica?"

"25è CONGRÉS DE LA SOCIETAT CATALANA

D'OFTALMOLOGIA". Barcelona, December 1994. 9.1.13.

Jordi Monés, Andreu Coret: “Técnica combinada de implante

secundario de LIO de cámara posterior por incisión corneal con vitrectomía pars plana y fijación transescleral”. “III CONGRESO DE LA SOCIEDAD ESPAÑOLA DE RETINA Y VITREO”. Madrid, February 21-22, 1997. 9.1.14.

Jordi Monés, Andreu Coret, Josep Ramon Soler: “Recolocación

interna con fijación escleral de LIO luxada a cámara vítrea mediante vitrectomía posterior”. “III CONGRESO DE LA SOCIEDAD ESPAÑOLA DE RETINA Y VITREO”. Madrid, February 21-22, 1997. 9.1.15.

Jordi Monés i Carilla, Andreu Coret Novoa: “ Técnica combinada

de cirugía del agujero macular y facoemulsificación e implante de LIO

C. Vitae Jordi Monés 32

de CP” “12º CONGRESO SECOIR”. Santander, April 23-26, 1997. 9.1.16.

Jordi Monés i Carilla, Josep Ramon Soler i Tomás: “ Técnica de

implante 2ºde LIO-CP con fijación transescleral mediante vitrectomía posterior.” “12º CONGRESO SECOIR”. Santander, April 23-26, 1997 9.1.17.

J. Monés, F. Huste, IH Tercero: “Tècnica d’implant secundari de

LIO amb fixació transescleral amb vitrectomia posterior” “4ª BIENNAL DE VIDEO OFTALMOLOGIA”. Girona, June 28, 1997. 9.1.18.

J. Monés, JR Soler Tomàs, JA Cardona: “Tècnica combinada

de cirurgia de forat macular i facoemulsificació i implant de LIO-CP” “4ª BIENNAL DE VIDEO OFTALMOLOGIA”. Girona, June 28, 1997. 9.1.19.

Jordi Monés Carilla, Andrés Coret. “Recolocación interna de LIO

luxada a cámara vítrea mediante vitrectomía posterior y fijación transecleral. LXXIII CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA". Granada, September 24-28, 1997. 9.1.20.

José Ramon Soler Tomás,

Jordi Monés Carilla.

“Técnica

combinada de cirugía de agujero macular y facoemulsificación de la catarata

con

implante

plegable

de

cámara

posterior”.

LXXIII

CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA". Granada, September 24-28, 1997. 9.1.21.

Jordi Monés Carilla. “Vitrectomía posterior sin suturas”

74

CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA. Alicante, September 30 - October 4, 1998. 9.1.22.

Jordi Monés i Carilla “Técnica de reparación inmediata de

luxación de núcleo durante la facoemulsificación: vitrectomía posterior e implante de lente intraocular con fijación escleral a través de pequeña incisión”. 74 CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA. Alicante, 30 Sept - Oct 4, 1998.

C. Vitae Jordi Monés 33

9.1.23.

Jordi Monés:

“Terapia Fotodinámica en DAME exudativa:

Resultados de pacientes en Uso compasivo.” ” 76 CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA.

Madrid, 11-15

October, 2000.

9.1.24. Jordi Monés I cols. Teràpia Fotodinàmica en DMAE: resultants de pacients en Fase d’ús Compassiu. 31 CONGRÉS DE LA SOCIETAT CATALANA D’OFTALMOLOGIA”. Barcelona, 23-24 November 2000.

(PRESENTATIONS and LECTURES are presented together from this point in the section 11.2) 9.2.

International Meetings:

9.2.1. Sena Dutrenit JM, Vilaplana D, Soler JR, Monés JM: "Resultados de la Fotocoagulación

Láser".

"IX

CURS

INTERNACIONAL

D'OFTALMOLOGIA DEL INSTITUT BARRAQUER".

Barcelona, May

1987. 9.2.2. David

R.

Guyer,

Carmen

A.

Puliafito,

Jordi

M.

Monés:

"Indocyanine-Green Digital Angiography and Dye-Enhanced Diode Laser

Photocoagulation

"ADVANCES

IN

PERSPECTIVE.

of

OCULAR

Choroidal

DRUG

Neovascularization".

THERAPY:

A

PRACTICAL

Massachusetts Eye and Ear Infirmary.

Harvard

Medical School. Boston, Massachusetts. USA, March 9, 1991. 9.2.3. David

R.

Guyer,

Carmen

A.

Puliafito,

Jordi

M.

Monés:

"Indocyanine-Green Digital Angiography and Dye-Enhanced Diode Laser Photocoagulation of Choroidal Neovascularization". WILMER RESIDENTS ASSOCIATION MEETING". Institute.

THE Wilmer

John Hopkins University, School of Medicine.

Maryland. USA. April 25-27, 1991.

"1991

Baltimore,

C. Vitae Jordi Monés 34

9.2.4. Wendall C. Bauman, Jordi M. Monés, Jean-Jacques Tritten, Charles P. Lin, Evangelos Gragoudas, Carmen A. Puliafito:

"Transpupillary

Phthalocyanine Photodynamic Therapy of Experimental Posterior Malignant Melanoma".

"1991 ANNUAL MEETING OF THE

ASSOCIATION

RESEARCH

FOR

IN

VISION

AND

OPHTHALMOLOGY, ARVO". Sarasotta, Florida. USA. April 28 - May 2, 1991. 9.2.5. Jordi M. Monés, William J. Woods and Carmen A Puliafito: "Retinal Toxicity of Hyaluronidase and Thimerosal injected into the Vitreous Body of the Rabbit".

"1991 ANNUAL MEETING OF THE

ASSOCIATION

RESEARCH

FOR

IN

VISION

AND

OPHTHALMOLOGY, ARVO". Sarasotta, Florida. USA. April 28 - May 2, 1991. 9.2.6. Carmen A. Puliafito, David R. Guyer, Jordi M. Monés, Yaffa Weaver: "Indocyanine-Green Digital Angiography and Dye-Enhanced Diode Laser Photocoagulation of Choroidal Neovascularization".

"1991

ANNUAL MEETING OF THE ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY, ARVO".

Sarasotta, Florida. USA.

April 28-May 2, 1991. 9.2.7. Ephraim Friedman, Jordi M. Monés: "The use of Indocyanine-Green in evaluating the Choroidal Circulation". "MASSACHUSETTS EYE AND EAR ALUMNI ASSOCIATION. ANNUAL CLINICAL AND SCIENTIFIC MEETING". Boston, Massachusetts. USA. May 16,1991. 9.2.8. David

R.

Guyer,

Carmen

A.

Puliafito,

Jordi

M.

Monés:

"Indocyanine-Green Dye Enhanced Diode Laser Photocoagulation of Choroidal Neovascularization". ALUMNI ASSOCIATION.

"MASSACHUSETTS EYE AND EAR

ANNUAL CLINICAL AND SCIENTIFIC

MEETING". Boston, Massachusetts. USA. May 16,1991. 9.2.9. Wendall C. Bauman, Jean-Jacques Tritten, Jordi M. Monés, Charles P.

C. Vitae Jordi Monés 35

Lin, Evangelos Gragoudas, Carmen A. Puliafito: PhotodynamicTherapy "MASSACHUSETTS ANNUAL

of EYE

CLINICAL

AND

Experimental AND

EAR

"Transpupillary

Malignant ALUMNI

SCIENTIFIC

Melanoma".

ASSOCIATION.

MEETING".

Boston,

Massachusetts. USA. May 16,1991.

9.2.10.

Jordi M. Monés, David R. Guyer, Carmen A. Puliafito, Ephraim

Friedman.

"Indocyanine-Green Angiography in Choroidal Diseases".

"1991 SCHEPENS INTERNATIONAL SOCIETY MEETING". Madrid, May 27-31, 1991. 9.2.11.

Jordi M. Monés, Wendall C. Bauman, Jean-Jacques Tritten,

Charles

P.

Lin,

Carmen

A.

Puliafito,

Evangelos

"Phthalocyanine Photodynamic Treatment of Experimental

Gragoudas: Posterior

Malignant Melanoma". "1991 SCHEPENS INTERNATIONAL SOCIETY MEETING". Madrid, May 27- 31, 1991. 9.2.12.

Carmen A. Puliafito, David R. Guyer, Jordi M. Monés: "Digital

Indocyanine-Green Angiography in retinal vascular diseases". "1991 ANNUAL

MEETING

OPHTHALMOLOGY".

OF

THE

AMERICAN

ACADEMY

OF

Anaheim, California. USA. October 13-17,

1991. 9.2.13.

Corcóstegui B, Monés JM: "Indocyanine videangiography with

Scanning Laser Ophthalmoscope of large choroidal vessels in exudative age-related macular degeneration."

"1994 ANNUAL

MEETING OF THE ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY, ARVO". Sarasotta, Florida. USA. May 1-6, 1994. 9.2.14.

Jordi M. Monés, Borja Corcóstegui:

"Submacular choroidal

vascular patterns in exudative age-related macular degeneration." "4th INTERNATIONAL SYMPOSIUM ON OCULAR CIRCULATION AND NEOVASCULARIZATION". Budapest, Hungary, May 22-26, 1995.

C. Vitae Jordi Monés 36

9.2.15.

Jordi Monés i Carilla, Josep Ramon Soler i Tomàs: “Implante

secundario con fijación transescleral mediante Vitrectomía Posterior” “CURSO INTERNACIONAL INSTITUTO BARRAQUER”.

Barcelona,

June 9-11, 1997.

9.2.16.

Jordi Monés, Andreu Coret, Josep Ramon Soler: “Recolocación

interna con fijación escleral de LIO luxada a cámara vítrea mediante vitrectomía

posterior”.

“CURSO

INTERNACIONAL

INSTITUTO

BARRAQUER”. Barcelona, June 9-11, 1997. 9.2.17.

JR Soler Tomàs, J Monés, A Cardona, F. Huste:

“Anillos

intracapsulares de tensión. Aplicaciones” “CURSO INTERNACIONAL INSTITUTO BARRAQUER”. Barcelona, June 9-11, 1997. 9.2.18.

Monés JM: Pars plana vitrectomy and scleral fixation of foldable

intraocular

lens

through

pahcoemulsification

of

fragments luxation.

small

dense

incision

cataract

during

with

complicated

intravitreal

nuclear

XVIth CONGRESS OF THE ESCRS.

Nice,

September 6-9, 1998. 9.2.19.

Monés J and the VIP Study Group.

Photodynamic therapy

(PDT) with Verteporfin of subfoveal choroidal neovascularization in agerelated

macular

degeneration:

Study

design

and

baseline

characteristics in the VIP randomized clinical trial. Invest Ophthalmol Vis Sci 40 (4) (Suppl): 1703 1999. 9.2.20.

Monés JM.

Reunión de

casos clínicos: Retina y Vítreo.

Andorra, January 2000. 9.2.21.

Monés JM. Principle Aspects of Clinical Trials of Photodynamic

Therapy with Verteporfin (VisudyneTM): Phase I and II, and phase III (TAP and VIP Study) in the treatment of CNV secondary to AMD y

C. Vitae Jordi Monés 37

Pathologic Myopia.

International Symposium Ocular Pharmacology.

and Pharmaceutics. Lisbon, February 12, 2000. 9.2.22.

Monés JM. One-year Angiographic Outcomes and Safety

Following Photodynamic Therapy with Verteporfin (Visudyne) for subfoveal choroidal neovascularization in AMD – Results of Two Randomized Phase III Clinical Trials (TAP Investigation) International Symposium

Ocular

Pharmacology.

and

Pharmaceutics.

Lisbon,

February 12, 2000. 9.2.23.

Monés JM. One-year Angiographic Outcomes and Safety

Following Photodynamic Therapy with Verteporfin (Visudyne) for subfoveal choroidal neovascularization in AMD – Results of Two Randomized

Phase

III

Clinical

Trials

(TAP

Investigation)

VI

Mediterranean Ophthalmological Society Congress and VI Michaelson Symposium on Ocular Circulation and Neovascualrization. Jerusalem, Israel, May 24, 2000. 9.2.24.

Photodynamic

Neovascularization

Therapy in

Pathologic

of

Subfoveal

Myopia

Using

Choroidal Verteporfin

(Visudynetm); One-year Results – VIP Report #1. The Retina Society 33RD Annual Meeting. Coral Gables, FLA, USA, November 30 December 3, 2000. 9.2.25.

Polypoidal Choroidal Vasculopathy in recurrent CNV after PDT.

The Retina Society 34rd Annual Meeting. Chiacago, USA October 1417 2001 (It was going to be presented, Meeting Cancelled due to September 11th 2001) 9.2.26.

Safety of multiple consecutive areas of light application during

treatment of CNV with PDT. Reinaldo Castillo, Javier Moreno,Gilberto Rosales, Fernanda Vaz, Jordi Monés. Euretina Meeting. Barcelona, May, 2002.

C. Vitae Jordi Monés 38

9.2.27.

Photodynamic therapy in myopic CNV. Euretina Meeting.

Barcelona, May, 2002. 9.2.28.

A

New

Automated

Quantified

Macular

Metamorphopsia

Measurement in CNV treated with PDT. 25th ANNUAL MACULA SOCIETY MEETING. Barcelona, June, 2002

9.2.29.

Analysis of safety data of three randomized Trials of Verteporfin

therapy in the treatment of neovascular AMD XXIIIrd Congress of the Club Jules Gonin in Montreux, Switzerland, 31 August - 4 Sep, 2002. (PRESENTATIONS and LECTURES are presented together from this point in the section 11.2) 10. TEACHING ACTIVITIES and INVITED LECTURES: 10.1. Organization of Scientific Courses: 10.1.1.

Co-organization Curso " NUEVAS TÉCNICAS DE EXAMEN DEL

FONDO DE OJO: LA OFTALMOSCOPÍA CON LÁSER DE BARRIDO (SLO)". Directores del Curso: Jordi Monés, Borja Corcóstegui. Centro Retina Vitreo, Barcelona, October 23, 1993. 10.1.2.

Fundator del “Club Angiográfico Fluoresceina – Indocianina,

Club FLIN” 10.1.3.

Organization I Reunión Club Angiográfico FLIN. October 1995,

Barcelona. 10.1.4.

Organization II Reunión Club Angiográfico FLIN.

September

1996, Madrid. 10.1.5.

Organization III Reunión Club Angiográfico FLIN.

September

1997, Granada. 10.1.6.

Co-organization

Curso:

Luxación

posterior

de

núcleos

C. Vitae Jordi Monés 39

(Facoemulsificación ) y de LIO. secundarios.

Directores:

Soluciones quirúrgicas.

Implantes

JR Soler Tomás, J Monés Carilla. LXXIII

CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA". Granada, September 24-28, 1997. 10.1.7.

Organization n IV Reunión Club Angiográfico FLIN. Alicante,

September 1988.

10.1.8.

Co-organization

I Reunión Grupo de Terapia Fotodinámica.

Venecia July 1999. 10.1.9.

Organization

V Reunión Club Angiográfico FLIN. Málaga,

September 1999. 10.1.10. LXXV

Co-organization Curso Angiografía con Verde de Indocianina. CONGRESO

DE

LA

SOCIEDAD

ESPAÑOLA

DE

OFTALMOLOGÍA". Málaga, September 22, 1999. 10.1.11.

Co-organization Curso Casos . LXXV CONGRESO DE LA

SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA". Málaga, September 22, 1999. 10.1.12.

Co-organization

II

Reunión

Grupo

de

Terapia

Fotodinámica.Deià, January, 2000. 10.1.13.

Co-organization III Reunión Grupo de Terapia Fotodinámica.

Valladolid, June 2000. 10.1.14.

Organization

VI Reunión Club Angiográfico FLIN. Madrid

October 2000. 10.1.15.

Chairperson Symposia: Visudyne: La Terapia Fotodinámica en

Oftalmología. 76 CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA. Madrid, 11-15 October, 2000. 10.1.16.

Coordinator: Round Table “Tratamiento con Láser, Terapeútica

C. Vitae Jordi Monés 40

Fotodinámica y Ayudas Visuales en DMAE. XI CONGRESO DE LA SOCIEDAD ARAGONESA DE OFTALMOLOGÍA.

Zaragoza, 10-11

November , 2000. 10.1.17.

Organization and Coordination of an Interactive Course (700

people) “Alternativas Terapeúticas de la Neovascularización Coroidea: Discusión de Casos Clínicos”

V CONGRESO DE LA SOCIEDAD

ESPAÑOLA DE RETINA Y VITREO. Madrid, 2- 3 -March, 2001 10.1.18.

Current Trials on Visudyne: 4th Int. Symp. on Ocular

Pharmacology and Pharmaceutics. Seville, March, 2002. 10.1.19.

Course: Clinical Cases. II European Congress of PDT.

Barcelona, September, 2002. 10.1.20.

Mesa redonda: "Avances en el tratamiento de la DMAE".

Moderador: Jordi Monés. Congreso Sociedad Española de Retina y Vítreo. Santiago de Compostela, March, 2004.

10.1.21.

Meeting New Horizons in AMD. Barcelona, March, 2005.

10.1.22.

Ponencia

Oficial

81

Congreso

Sociedad

Española

de

Oftalmología, “La degeneración macular asociada a la edad”. Zaragoza, Sept, 2005. 10.1.23.

Actualización en DMAE. Directores: Jordi Monés i Carilla,

Francisco Gómez-Ulla de Irazazábal Nivel: Avanzado. 83 Congreso de la Sociedad Española de Oftalmologia. Las Palmas de Gran Canaria, Sept 26-29 , 2007. 10.1.24.

Jordi Monés, Bayer Educational Slide Development/Speaker

Training. Vancouver, January 21-22, 2012.

10.2. Invited Lectures and invited participation in Courses: 10.2.1.

Lecture: "Exploración Angiogràfica de la Coroides". I CURSO

C. Vitae Jordi Monés 41

DE PATOLOGÍA E INVESTIGACIÓN VÍTREAS. Valladolid, May 23-25, 1991. 10.2.2.

Lecture: "Angiografía con indocianina verde mediante SLO en la

DMAE".

CURS

DE

DOCTORAT 1993

- 94,

UNIVERSITAT

AUTÒNOMA DE BARCELONA, HOSPITAL DE LA VALL D'HEBRON. Barcelona, April 1993.

10.2.3.

Discussion Poster Presentation: LXIX CONGRESO DE LA

SOCIEDAD

ESPAÑOLA

DE

OFTALMOLOGÍA.

Santiago

de

Compostela, October 3, 1993. 10.2.4.

Lecture: "AFG del Futuro". CURSO TEÓRICO-PRÁCTICO DE

LASERTERAPIA BÁSICA ARGON-YAG EN OFTALMOLOGÍA. Elx, October 22, 1993. 10.2.5.

Lecture: "Principios de la angiografía con indocianina verde".

Curso " NUEVAS TÉCNICAS DE EXAMEN DEL FONDO DE OJO: LA OFTALMOSCOPÍA CON LÁSER DE BARRIDO (SLO)". Centro Retina Vitreo. Barcelona, October 23, 1993. 10.2.6.

Lecture: "Angiografía con indocianina verde mediante SLO en la

DMAE". Curso " NUEVAS TÉCNICAS DE EXAMEN DEL FONDO DE OJO:

LA OFTALMOSCOPÍA CON LÁSER DE BARRIDO (SLO)".

Centro Retina Vitreo. Barcelona, October 23, 1993. 10.2.7.

Lecture: "Oftalmoscopia con Láser de Barrido (SLO)." "CURSO

DE ACTUALIZACIÓN EN OFTALMOLOGÍA", HOSPITAL PUERTA DE HIERRO. Madrid, December 11, 1993. 10.2.8.

Lecture: "Detección de neovasos subretinianos utilizando verde

de indocianina con el SLO". "CURSO DE AVANCES EN TÉCNICAS QUIRÚRGICAS

DE

MICROCIRUGÍA

OCULAR".

Autònoma de Barcelona. Barcelona, March 18, 1994.

Universitat

C. Vitae Jordi Monés 42

10.2.9.

Lecture:

"Angiografía con indocianina verde - SLO en la

degeneración macular asociada a la edad". "SEMINARIO DEL MES DE JUNIO"

HOSPITAL UNIVERSITARIO, DE

VALLADOLID. Valladolid, June 25, 1994. 10.2.10.

Round Table: "MESA REDONDA:

Nuevos Métodos de

Exploración Retiniana". Participantes: Bertoja E, Marín F, Monés J, Scheider A.

Moderador:

Gómez-Ulla F. LXX CONGRESO DE LA

SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA. Tenerife, September 30 - October 4, 1994. 10.2.11.

Lecture: "Aplicaciones del Oftalmoscopio de Làser de Barrido

para las patologías de la Mácula". "JORNADAS CIENTÍFICAS 50 ANIVERSARIO DE LA FUNDACIÓN DE LA CLÍNICA QUIRÓN". Barcelona, November 12, 1994. 10.2.12.

Lecture:

"Exploración de la circulación coroidea mediante

Videoangiografía con Verde de Indocianina - SLO"

"CURSO DE

ANGIOGRAFÍA Y LÀSER EN PATOLOGÍA DE LA RETINA". Santiago de Compostela, November 17-19, 1994. 10.2.13.

Lecture:

"Videoangiografía - SLO en las enfermedades

inflamatorias de la coroides y epitelio pigmentario". "CURSO DE ANGIOGRAFÍA Y LÀSER EN PATOLOGÍA DE LA RETINA". Santiago de Compostela, November 17-19, 1994 10.2.14.

Lecture: "Clasificación de los patrones angiográficos con AVI -

SLO en las membranas neovasculares de la DMAE”. "CURSO DE ANGIOGRAFÍA Y LÀSER EN PATOLOGÍA DE LA RETINA". Santiago de Compostela, November 17-19, 1994. 10.2.15.

Lecture: "Circulación coroidea de las formas exudativas de la

DMAE mediante VAGF-SLO."

"CURSO DE ANGIOGRAFÍA Y LÀSER

EN PATOLOGÍA DE LA RETINA". Santiago de Compostela, November 17-19, 1994.

C. Vitae Jordi Monés 43

10.2.16.

Lecture:

"Oftalmoscopía làser de barrido (SLO) en el

diagnóstico y tratamiento de las patologías maculares". "SIMPOSIUM MONOGRÁFICO SOBRE LA MÁCULA:

NUEVAS TÉCNICAS

DIAGNÓSTICAS Y TERAPEÚTICAS". Valencia, January 14, 1995. 10.2.17.

Round Table: "MESA REDONDA: Angiografía con verde de

Indocianina en la práctica oftalmológica".

Participantes:

Flower R,

Guyer D, Marín F, Monés J, Ruiz-Moreno JM. Moderador: Gómez-Ulla F. " II CONGRESO DE LA SOCIEDAD ESPAÑOLA DE RETINA Y VÍTREO". Madrid, February 24 - 25, 1995. 10.2.18.

Lecture: " Angiografia amb indocianina verda: Avantatges i

aplicacions".

"Departament

d'Oftalmologia

Clínica

L'Aliança".

Barcelona, March 31, 1995. 10.2.19.

Lecture: “Degeneració macular senil lligada a l’edat. Aspectes

clínics.

Angiografies. SLO.

“II JORNADA OFTALMOLOGICA DE

TARRAGONA: Lesions Maculars i Baixa visió”. Tortosa, May 4, 1996. 10.2.20.

Lecture:

"Utilidad del Scanning Laser Ophthalmoscope en el

diagnóstico diferencial de los tumores intraoculares". "CURSO DE AVANCES EN EL TRATAMIENTO MÉDICO Y QUIRÚRGICO DE LOS TUMORES INTRAOCULARES".

Institut de Microcirurgia Ocular de

Barcelona. Barcelona, June 2-3, 1995. 10.2.21.

Lecture:

Técnicas

"Angiografía con indocianina verde. En: Uveitis:

diagnósticas

IMMUNOLOGIA

y

OCULAR.

de

tratamiento".

MONOGRÁFICO:

"IV

CURSO

UVEITIS."

DE

IOBA,

Universidad de Valladolid. Sevilla, June 21-23, 1995. 10.2.22.

Lecture: Scanning laser, angiografía con verde de indocianina y

microperimetría”. “TECNICAS DIAGNOSTICAS EN OFTALMOLOGIA”. Pamplona, January 19-20, 1996. 10.2.23.

Lecture: “Aplicaciones de la AVI en el diagnóstico y tratamiento

C. Vitae Jordi Monés 44

de

las

membranas neovasculares

subretinianas”

“FORMACION

MEDICA CONTINUADA DEL ILMO. COL. MEDICOS ALICANTE. ACTUALIZACION EN ANGIOGRAFIA”. Alicante, February 3, 1996. Course: “ Curso avanzado sobre angiografía con indocianina

10.2.24. verde”

“1º CURSO DE LA SOCIEDAD ESPAÑOLA DE RETINA Y

VITREO”. Valladolid, February 24, 1996. Round Table:

10.2.25.

SOCIEDAD

“Retina Médica”. VII CONGRESO DE LA

ARAGONESA

DE

OFTALMOLOGIA.

Zaragoza,

November 15-16, 1996. Lecture: “Protocolo de la Terapia Fotodinámica” Mesa Redonda

10.2.26.

MACULA.

III CONGRESO DE LA SOCIEDAD ESPAÑOLA DE

RETINA Y VITREO. Madrid, February 21-22, 1997.

Lecture:

10.2.27.

“Verde

de

inflamatorias intraoculares”.

indocianina

en

las

enfermedades

“AVANCES EN EL DIAGNOSTICO Y

TRATAMIENTO DE LA INFLAMACION OCULAR”. Barcelona, May 23, 1997. 10.2.28.

Round Table:

“Degeneración macular asociada a la edad.

Terapia fotodinámica en las formas exudativas de la DMAE”. LXXIII CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA. Granada, September 24-28, 1997. 10.2.29.

Discussion Poster Presentation

LXXIII CONGRESO DE LA

SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA. Granada, September 25, 1997. 10.2.30. LA

Course: “LIO en ausencia de cápsula” LXXIII CONGRESO DE SOCIEDAD

ESPAÑOLA

DE

OFTALMOLOGÍA.

Granada,

September 25, 1997. 10.2.31.

Course: La angiografía con indocianina en la préactica clínica.

C. Vitae Jordi Monés 45

LXXIII

CONGRESO

DE

LA

SOCIEDAD

ESPAÑOLA

DE

OFTALMOLOGÍA. Granada, September 25, 1997. 10.2.32.

Lecture: “Hallazgos angiográficos mediante verde de indocianina

en las enfermedades inflamatorias coroideas”. CURSO “LA MÁCULA: DIAGNÓSTICO Y TRATAMIENTO QUIRÚRGICO”.

Hospital Clínic i

Universitari. Valencia, January 16-17, 1998. 10.2.33.

Lecture: “Terapia fotodinámica mediante verteporfina para el

tratamiento de las formas exudativas subfoveales de la degeneración macular asociada a la edad”. CURSO “LA MÁCULA: DIAGNÓSTICO Y TRATAMIENTO QUIRÚRGICO”.

Hospital Clínic i Universitari.

Valencia, January 16-17, 1998. 10.2.34.

Lecture: “Terapia fotodinámica mediante verteporfina para el

tratammiento de las formas exudativas subfoveales de la degeneración macular asociada a la edad”.

SEMINARIO.

DEPARTAMENTO DE

OFTALMOLOGIA, FACULTAD DE MEDICINA DE VALLADOLID. Valladolid, January 24, 1998. 10.2.35.

Clinical Cases:

Presentación interactiva de casos clínicos: II

CURSO DE LA SOCIEDAD ESPAÑOLA DE RETINA Y VÍTREO. Sevilla, February 28, 1998. 10.2.36.

Lecture: “Terapia Fotodinámica en la Neovascularización

Coroidea”.

CURSO

QUIRÚRGICA.

DE

POSTGRADO

Casos Especiales.

RETINA

MÉDICA

Y

Institut Universitari Barraquer.

Barcelona, March 28, 1998. 10.2.37.

Lecture: “Terapia Fotodinámica en la Neovascularización

Coroidea”.

NUEVAS PERSPECTIVAS EN LA DEGENERACIÓN

MACULAR ASOCIADA A LA EDAD.

Instituto Clínico Quirúrgico de

Oftalmología. Bilbao, April 25, 1998. 10.2.38.

Round Table: “Estado Actual de la Patología Macular”. XXX

C. Vitae Jordi Monés 46

CONGRESO DE LA SOCIEDAD OFTALMOLÓGICA DE ANDALUCIA Y EXTREMADURA. Marbella, June 26-28, 1998. 10.2.39.

Course:

“Alternativas terapeúticas de la DMAE”.

74

CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGIA. Alicante, Sept 30 -October 4, 1998. 10.2.40.

Course:

“ Angiografía con verde de indocianina”.

74

CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGIA. Alicante, Sept 30 - October 4, 1998. 10.2.41.

Lecture: “Avances en el diagnóstico y tratamiento no quirúrgico

de las enfermedades de la mácula.” I CURSO DE ACTUALIZACIÓN EN EL DIAGNOSTICO Y TRATAMIENTO DE LAS ENFERMEDADES DE LA MACULA. Sociedad Canaria de Oftalmología. Las Palmas, November 27-28, 1998. 10.2.42.

Lecture: Terapia Fotodinámica: Nuevas Técnicas Quirúrgicas e

Instrumentos.

IV CONGRESO DE LA SOCIEDAD ESPAÑOLA DE

RETINA Y VÍTREO. Madrid, February 19-20, 1999. 10.2.43.

Lecture: “Nou tractament de la degeneració macular. Terapia

Fotodinámica” Hospital de la Creu Roja. Barcelona, March 10, 1999. 10.2.44.

Lecture: Oclusiones coroideas asociadas al tratamiento de la

neovascularización subretiniana.

III Curso Internacional de Retina

Médica y Diabetes Ocular. Santiago de Compostela, April 23-24, 1999. 10.2.45.

Lecture: Terapia Fotodinámica en la DMAE.

Resultados

preliminares. III Curso Internacional de Retina Médica y Diabetes Ocular. Santiago de Compostela, April 23-24, 1999. 10.2.46.

Training Course:

Introducción a la Terapia Fotodinámica y

Resultados Ensayo Clínico Fase I y Fase III TFD. Curso – I Reunión Grupo de Terapia Fotodinámica. Venecia, July 1999. 10.2.47.

Training Course Descripción Ensayo Clínico Fase III TFD. Curso

C. Vitae Jordi Monés 47

– I Reunión Grupo de Terapia Fotodinámica. Venecia, July 1999. 10.2.48.

Training Course Resultados Ensayo Clínico Fase III TFD. Curso

– I Reunión Grupo de Terapia Fotodinámica. Venecia, July 1999. 10.2.49.

Training Course Presentación de casos clínicos.

Revisión

criterios de inclusión TFD en uso compasivo. Curso- I Reunión Grupo de Terapia Fotodinámica. Venecia, July, 1999. 10.2.50.

Training Course: Fundamentals of Photdynamic Therapy (TFD).

Training course VIT

(Verteporfin Italy Trial). Sardinia, September,

1999. 10.2.51.

Training Course: Phase I-III of Photodynamic Therapy with

Verteporfin. Training course VIT

(Verteporfin Italy Trial). Sardinia,

September, 1999. 10.2.52.

Training Course: Case presentation. Phase I and phase II of

Photodynamic

Therapy

with

Verteporfin.

Training

course

VIT

(Verteporfin Italy Trial). Sardinia, September, 1999.

10.2.53.

Course:

Angiografía

con

Verde

de

Indocianina.

LXXV

CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA". Málaga, September 22, 1999. 10.2.54.

Course: Casos clínicos . LXXV CONGRESO DE LA SOCIEDAD

ESPAÑOLA DE OFTALMOLOGÍA". Málaga, September 22, 1999. 10.2.55.

Discussion Poster Presentation: LXXV CONGRESO DE LA

SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA.

Málaga, September

24, 1999. 10.2.56.

Round

Table.

Terapia

Fotodinámica

con

Verteporfin.

Symposium Degeneración Macular Asociada a la Edad. LXXV CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA. Málaga, September 24, 1999.

C. Vitae Jordi Monés 48

10.2.57.

Visudyne Therapy. CibaVision in-booth theather.

American

Academy of Ophthalmology. Orlando, USA. October 25, 1999. 10.2.58.

Round Table:

Degeneració macular associada a l’edat:

possibilitats actuals de tractament.

Terapia Fotodinámica. Aplicació

actual. 30 Congrés de la Societat Catalana d’Oftalmologia. Barcelona, November 25-27, 1999. 10.2.59.

Lecture: Terapia Fotodinámica con Verteporfin. XLII Congresso

de la Sociedade Portuguesa de Oftalmologia. Lisboa, December 1-4, 1999. 10.2.60.

Lecture: Principles of Photodynamic Therapy. “Photodynamic

Therapy Leaders Symposium”. Vienna, December 11, 1999. 10.2.61.

Lecture:

Estado actual del uso compasivo de la Terapia

Fotodinámica para el tratamiento de la neovascularización coroidea secundaria a DMAE. Mallorca, January, 2000

10.2.62.

Lecture: Ull vermell i Glaucoma.

XII Curs de Formació

Continuada. Actualitzacions diagnòstiques i Terapeútiques. Hospital de Mataró . Barcelona, February 24, 2000. 10.2.63.

Lecture:

Estat

actual

de

la

Terapia

Degeneració Macular Asociada a la Edad.

Fotodinámica

en

XII Curs de Formació

Continuada. Actualitzacions diagnòstiques i Terapeútiques. Hospital de Mataró. Barcelona, February 24, 2000 10.2.64.

Course: DECISIONES TERAPEÚTICAS siguiendo CRITERIOS

ANGIOGRÁFICOS. Curso Angiografía y su Implicación Terapeútica en DMAE. Curso de la Sociedad Española de Retina Vítreo. Bilbao, February 26, 2000. 10.2.65.

Lecture:

Estado

actual

Terapia

Fotodinámica.

Sesión

Degeneración Macular Asociada a la Edad. Curso de la Sociedad

C. Vitae Jordi Monés 49

Española de Retina Vítreo. Bilbao, February 26, 2000. 10.2.66.

Lecture: One-year results of TAP Study of Photodynamic

Therapy with Verteporfin. Vitreoretinal Interface Course. Rome, March 31, 2000. 10.2.67.

Lecture: Estado Actual de la Terapia Fotodinámica. Symposium

de Terapia Fotodinámica con Verteporfin.

Buenos Aires, Argentina.

May 11, 2000. 10.2.68.

Lecture: Estado Actual de la Terapia Fotodinámica. Curso de

Perfeccionamiento

para

Oftalmólogos.

Sociedad

Chilena

de

Oftalmología. Santiago de Chile, Chile. May 12, 2000. 10.2.69.

Lecture:

angiográficos

Decisiones en

DMAE.

Terapeúticas Curso

de

siguiendo

criterios

Perfeccionamiento

para

Oftalmólogos. Sociedad Chilena de Oftalmología. Santiago de Chile, Chile. May 12, 2000. 10.2.70.

Breakfast with Experts:

Perfeccionamiento

para

Terapia Fotodinámica. Curso de

Oftalmólogos.

Sociedad

Chilena

de

Oftalmología. Santiago de Chile, Chile. May 12, 2000. 10.2.71.

Resultados Uso Compasivo Terapia Fotodinámica en DMAE.

Curso Nuevos Avances en el Diagnóstico y Tratamiento quirúrgico en Oftalmología. Servicio Oftalmología Hospital Vall d’Hebrón. Barcelona, May 19- 20, 2000. 10.2.72.

Lecture: Protoporfirinas en la DMAE.

Degeneraciones y Distrofias Retinianas.

Actualización en

IOBA. Valladolid, June-3,

2000. 10.2.73.

Lecture:

Terapia Fotodinámica en miopía.

Miopía 2000.

Asociación Oftalmológica del Norte. Vitoria, Spain. June 9, 2000. 10.2.74.

Lecture: Fundamentals of Photodynamic Therapy.

Course on PDT. Cannes, France. June 10, 2000.

Creteil

C. Vitae Jordi Monés 50

10.2.75.

Lecture:

Photodynamic Therapy in Myopia:

VIP Trial.

UK

Visudyne Symposium. Geneve, September 30, 2000. 10.2.76.

Compassionate use in Barcelona of Photodymanic Therapy: 1

year results. UK Visudyne Symposium. Geneve, September 30, 2000.

10.2.77.

TAP Study. 2-year angiographic results. Symposia: Visudyne:

La Terapia Fotodinámica en Oftalmología. 76 CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA. Madrid, 11-15 October, 2000. 10.2.78.

Terapia Fotodinámica: 1 año de resultados en Fase de Uso

Compasivo en Barcelona.

Symposium Visudyne:

La Terapia

Fotodinámica en Oftalmología. 76 CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA. Madrid, October 14, 2000. 10.2.79.

Decisiones

angiográficos. Edad.

76

Terapeúticas

para

la

DMAE

sobre

criterios

Symposium en Degneración Macular Asociada a la

CONGRESO

DE

LA

SOCIEDAD

ESPAÑOLA

DE

OFTALMOLOGÍA. Madrid, October 15, 2000.

10.2.80.

Desayuno con expertos. Degeneración Macular Asociada a la

edad.

76 CONGRESO DE LA SOCIEDAD ESPAÑOLA DE

OFTALMOLOGÍA. Madrid, October 14, 2000. 10.2.81.

Terapia Fotodinámica Estudio TAP: Resultados 2 años.

Reunión Satélite AMERICAN ACADEMY OF OPHTHALMOLOGY MEETING 2000, Symposium Visudyne Iberoamérica. Dallas, October 23, 2000. 10.2.82.

Instructor Skill transfer Program:

Photodynamic Therapy:

Current treatment guidelines for choroidal neovascularization. Course HO-601. AMERICAN ACADEMY OF OPHTHALMOLOGY MEETING.

C. Vitae Jordi Monés 51

Dallas, October 25, 2000. 10.2.83.

Terapéutica Fotodinámica.

Experiencia personal y Estudio

multicéntrico. XI CONGRESO DE LA SOCIEDAD ARAGONESA DE OFTALMOLOGÍA. Zaragoza, November 10-11, 2000. 10.2.84.

Mesa Redonda “Terapéuticas Acctuales en la Degeneración de

Mácula asociadas a la Edad” REUNION ANUAL DE LA ASOCIACIÓN OFTALMOLÓGICA DEL NORTE. Bilbao, November 18, 2000. 10.2.85.

Terapia Fotodinàmica amb Verteporfino en DMAE. Estudi TAP:

Resultats de 2 anys. Satellite Symposium 31 CONGRÉS DE LA SOCIETAT CATALANA D’OFTALMOLOGIA”. Barcelona, November 23-24, 2000. 10.2.86.

Experiencia en Terapia Fotodinámica en Oftalmología.

CONGRESO DE LASER EN MEDICINA Y CIRUGÍA.

X

México DF,

México. November 28 , 2000. 10.2.87.

Estado Actual de Ensayos Clínicos en la Neovascularización

Coroidea

SESION CLÍNICA INSTITUT MICROCIRURGIA OCULAR

DE BARCELONA. Barcelona, February, 2001.

10.2.88.

Estado Actual de Ensayos Clínicos en la Neovascularización

Coroidea. V CONGRESO DE LA SOCIEDAD ESPAÑOLA DE RETINA Y VITREO. Madrid, March 2- 3, 2001 10.2.89.

Lecture:

TREATMENT

The TAP Study. OF

AGE-RELATED

NEW ASPECTS IN THE MACULAR

DEGENERATION.

Rome, March 10, 2001. 10.2.90.

Terapia Fotodinámica en Miopía y Degeneración Macular

Asociada a la Edad ( Estudio VIP, resultados a 24 meses ). III CURSO INTERNACIONAL

“LO

ACTUALMENTE

POSIBLE

EN

ENFERMEDADES VITREORRETINIANAS” México DF, México. 22-24

C. Vitae Jordi Monés 52

de Marzo 2001. 10.2.91.

Ensayo Clínico de la Degeneración Macular Asociada a la Edad

(Estudio TAP) Resultados a 36 meses ). III CURSO INTERNACIONAL “LO

ACTUALMENTE

POSIBLE

EN

ENFERMEDADES

VITREORRETINIANAS” México DF, México. March 22-24, 2001.

10.2.92.

Management of Visudyne Therapy:

Treatment and follow-up

procedures. Course Visudyne therapy for Neovascular Disorders of the Macula – Introduction to Visudyne Therapy.

XIII Congress of The

European Society of Ophthalmology. Istanbul, June -7, 2001. 10.2.93.

Visudyne Therapy in Pathologic Myopia: 24-month Update from

VIP Study. Symposia Visudyne in Clinical Practice: Trial Updates and Recommended Patient Management. XIII Congress of The European Society of Ophthalmology. Istanbul, June -7, 2001. 10.2.94.

Control del Paciente.

Indicación de los retratamientos.

Simposium sobre Fototerapia Dinámica. GLADAOF Meeting. Buenos Aires, July 21, 2001. 10.2.95.

Paper: Visudyne Therapy in Patients with AMD: Experience from

Trials and Clinical Practice. 77 CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA. Barcelona, October, 2001. 10.2.96.

Lecture: Current and Future Treatments in AMD. Challenges In

PDT For Choroidal Neovascularisation, Liverpool Medical Institution. Liverpool, October 16, 2001. 10.2.97.

Lecture: Terapia Fotodinàmica en DMAE: Patología de la

Mácula, Alicante, October 19,2001.. 10.2.98.

Lecture: Current and Future Treatments in AMD. Curso

Actualizaçáo Oftalmológica. Lisboa, October 27, 2001.

C. Vitae Jordi Monés 53

10.2.99.

Clinical Session.Casos Clínicos: Retratamientos TFD en NVC –

Miopía.Monitorización Metamorfopsia. I.M.O. Barcelona, January 29, 2002 10.2.100.

Polypoidal Choroidal Vasculopathy in recurrent CNV after PDT

Clinical Session. Reunió Hivern Retina de Barcelona. Baqueira, February, 2002.

10.2.101.

Anti-VEGF in exudative AMD 4th Int. Symp. On Ocular

Pharmacology and Pharmaceutics. Seville, March, 2002. 10.2.102.

Decision

making

in

PDT

retreatments.

Monitoring

metamorphopsia. 4th Int. Symp. On Ocular Pharmacology and Pharmaceutics,Seville, March 2002 10.2.103.

Current trials on Visudyne. 4th Int. Symp. On Ocular

Pharmacology and Pharmaceutics. Seville, March, 2002. 10.2.104.

Discussion Paper: Lluis Arias, TFD en C.S.U. Bellvitge:

Resultados en DMAE y MP. VI CONGRESO DE LA SOCIEDAD ESPAÑOLA DE RETINA Y VITREO. San Sebastián, March, 2002. 10.2.105.

Current and FutureTreatments in AMD. Padova, April 4, 2002.

10.2.106.

Principles of Photodynamic Therapy. TÜRK OFTALMOLOJI

DERNEGI. Ankara, April, 2002.

10.2.107.

Visudyne Therapy in Patients with AMD:Experience from Trials

and Clinical Practice. TÜRK OFTALMOLOJI DERNEGI. Ankara, April, 2002. 10.2.108.

Photodynamic Therapy with Verteporfin in AMD. Experience

from Trials and Clinical Practice. TÜRK OFTALMOLOJI DERNEGI. Ankara, April, 2002.

C. Vitae Jordi Monés 54

10.2.109.

Treatment Response — Beyond Visual Acuity. International

Congress in Opthalmlogy. Sidney, Australia. April, 2002. 10.2.110.

Terapia Fotodinámica. Retratamientos. Actualización en el

diagnóstico y tratamientos de complejos neovasculares subretinianos. Madrid, May 11, 2002. 10.2.111.

Visudyne Therapy in Patients with AMD:Experience from Trials

and Clinical Practice. Actualización en el diagnóstico y tratamientos de complejos neovasculares subretinianos. Madrid, May 11, 2002. 10.2.112.

Current Trials on Visudyne: Rationale for VER and VIM Study.

Actualización

en

el

diagnóstico

y

tratamientos

de

complejos

neovasculares subretinianos. Madrid, May 11, 2002. 10.2.113.

Practical algorithms on PDT retreatment in AMD and myopia.

G.I.V.R.E. Course. Parma, May, 2002. 10.2.114.

Course: Clinical Cases. II European Congress of PDT.

Barcelona, September, 2002. 10.2.115.

Clinical

Session:

Tratamientos

vasos

nutricios

en

Neovascularización coroidea. I.M.O. Barcelona, December 10, 2002. 10.2.116.

Tratamiento de la neovascularización coroidea: Actividad de alto

riesgo? Curso Actualización DMAE. Sevilla, January 25, 2003. 10.2.117.

Tratamiento de la neovascularización coroidea: Actividad de alto

riesgo? VII CONGRESO DE LA SOCIEDAD ESPAÑOLA DE RETINA Y VITREO. Madrid, February 27, 2003.

10.2.118.

Clinical Session: The Anecortave Acetate for Exudative AMD:

Clinical Outcomes and Status of Clinical Studies. I.M.O. Barcelona, May, 2003. 10.2.119.

Lecture: The Anecortave Acetate for Exudative AMD: Clinical

C. Vitae Jordi Monés 55

Outcomes and Status of Clinical Studies. 14th Congress of The European Society of Ophthalmology. Madrid, June, 2003 10.2.120.

Lecture: Is Lesion Size as Important as Lesion Composition?

14th Congress of The European Society of Ophthalmology. Madrid, June 2003 10.2.121.

Lecture: The Anecortave Acetate for Exudative AMD: Clinical

Outcomes and Status of Clinical Studies. Firenze, September 4, 2003. 10.2.122. for

Lecture: Preferential Hyperacuity Perimetry (PHP): A new way monitoring

CNV

progression.

VI

INTERNATIONAL

CONGRESS:Myopia and Related Diseases: A clinical and therapeutic approach. Rome. September, 2003 10.2.123.

Lecture: Implications of contrast sensitivity preservation in AMD

patients treated with Visudyne therapy. III European Congress on PDT in AMD Management. Cannes, October 3-4, 2003. 10.2.124.

PDT using delayed light application in occult lesions: Results

from VALIO. III European Congress on PDT in AMD Management. Cannes, October 3-4, 2003. 10.2.125.

Clinical Session: Translocación Macular asociado a Terapia

Fotodinámica en NVC 2ria a Miopia Patológica. I.M.O. Barcelona, October 14, 2003. 10.2.126.

Course:

Translocación

Macular

asociado

a

Terapia

Fotodinámica en NVC 2ria a Miopia Patológica. 79 CONGRESO DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLCGÍA.

Valencia, October

2003.

10.2.127.

Lecture: Is Lesion Size as Important as Lesion Composition? V

Reunión Club Visudyne. Las Vegas USA, November, 2003.

C. Vitae Jordi Monés 56

10.2.128.

Management of AMD, Training course for the Alcon company

executives. Barcelona, December, 2003

10.2.129.

Current management in AMD, QLTI Analyst and Investor

Meeting. New York, December, 2003.

10.2.130.

Tratamiento

NVC

en

la

Retinopatía

Diabética.

Curso

Oftalmodiabetes, Hospital de l’Esperança. Barcelona, February, 2004

10.2.131.

Preferential Hyperacuity Perimetry (PHP) for monitoring myopic

CNV treated with PDT. 2004 Annual Meeting Macula Society. Las Vegas, 2004.

10.2.132.

Mesa redonda: "Avances en el tratamiento de la DMAE

".Moderador: Jordi Monés. Congreso Sociedad Española de Retina y Vítreo. Santiago de Compostela, March, 2004.

10.2.133.

Terapia

Fotodinámica

y

Corticoides.

Congreso

Sociedad

Española de Retina y Vítreo. Santiago de Compostela, March, 2004.

10.2.134.

Tratamiento antiangiogénico en DMAE. Congreso Sociedad

Española de Retina y Vítreo. Santiago de Compostela, March, 2004.

10.2.135.

PDT New drugs. Panel discussion. ISOPT Meeting, Montecarlo,

March, 2004.

10.2.136.

Refining Management of CNV due to AMD − Maximising Patient

Benefit through Prompt and Appropriate Treatment. ISOPT Meeting, Montecarlo, March, 2004.

C. Vitae Jordi Monés 57

10.2.137.

Tratamiento combinado:TFD + triamcinolona IVIT en NVC.

Sesión Clínica IMO, Barcelona, March, 2004.

10.2.138.

Curso Angiográfico Hospital de Sant Pau. Barcelona, April, 2004

10.2.139.

Terapia Antiangiogénica. Curso Macula. Institut Oftalmologia

Barraquer, June, 2004.

10.2.140.

Terapia

Antiangiogénica.

Curso

Instituto

Fernández-Vega.

Oviedo, June 2004.

10.2.141.

Terapia combinada, PDT y triamcinolona. Reunión de trabajo

Club Visudyne. Sitges, September 2004.

10.2.142.

Chair: Jordi M. Mones, MD,Section II: Photodynamic Therapy

and Corticosteroids for AMD. Subspecialty day Retina, Annual Meeting of the American Academy of Ophthalmology. New Orleans, USA. October 2004.

10.2.143.

Pfizer Macugen Worldwide Advisory Board. New Orleans, USA.

October 2004.

10.2.144.

Preferential Hyperacuity Perimetry for monitoring CNV. Couse

(E. Midena) at the Annual Meeting of the American Academy of Ophthalmology. New Orleans, USA October 2004.

10.2.145.

Efficacy of Macugen. Reunión Mexican Advisory Board.

Cuernavaca, México. October, 2004.

10.2.146.

Safety of Macugen. Efficacy of Macugen. Reunión Mexican

Advisory Board. Cuernavaca, México. October, 2004.

C. Vitae Jordi Monés 58

10.2.147.

Meeting of the European Group for the guidelines of treatment of

AMD. Paris, November, 2004.

10.2.148.

Clinical cases presentation. Soc. Lombarda oftalmologia. Milan

December, 2005.

10.2.149.

Curso Formación Degeneración Macular asociada a a la edad,

Pfizer. Madrid, December, 2004

10.2.150.

Sesión clínica IMO. Fármacos intravítreos. IMO. Barcelona,

January, 2005.

10.2.151.

Casos clínicos. Andorra, February 2005.

10.2.152.

Tratamiento Combinado en NVC: Terapia Fotodinámica y

Triamcinolona transeptal. Reunión Sociedad Española de Retina y Vítreo, Madrid, February, 2005.

10.2.153.

Curso satélite para oftalmólogos “Perimetría de Hiperagudeza

Preferencial”. Reunión Sociedad Española de Retina y Vítreo. Madrid, February, 2005.

10.2.154.

Curso satélite para ópticos y periodistas. “Perimetría de

Hiperagudeza Preferencial”. Reunión Sociedad Española de Retina y Vítreo. Madrid February, 2005.

10.2.155.

Clinical case presentation session. Meeting New Horizons in

AMD. Barcelona, March, 2005.

10.2.156.

Anti-VEGF therapy: clinical efficacy and safety of Macugen

C. Vitae Jordi Monés 59

New Horizons in AMD. Barcelona, March, 2005.

10.2.157.

Esquema

diagnóstico

y tratamiento

en DMAE.

Reunión

Panamerican Academy of Ophthalmology. Santiago de Chile, March, 2005.

10.2.158.

Update in Macugen, Reunión Panamerican Academy of

Ophthalmology. Santiago de Chile, March, 2005.

10.2.159.

Macugen therapy. Sessió clínica Hospital de la Vall d’Hebró.

April 2005

10.2.160.

Update in Macugen. Euretina Meeting. Barcelona, May, 2005.

10.2.161.

Limitations of intravitreal triamcinole as adjuntive therapy with

PDT. Meeting “Retina in Progress” Prof. A Pecce. Milan, Italy, June, 2005.

10.2.162.

Terapia antiangiogénica. Sesión clínica Hospital de l’Esperança.

Barcelona, June, 2005.

10.2.163.

Limitaciones de la triamcinolona intravítrea. Curso de la APEC,

Ciudad de México. México, September 2005.

10.2.164.

Perimetría de hiperagudeza preferencial. Curso de la APEC,

Ciudad de México. México, September, 2005

10.2.165.

Esquema diagnóstico y terapeútico de la DMAE. Curso de la

APEC, Ciudad de México. México, September, 2005.

C. Vitae Jordi Monés 60

10.2.166.

Tratamiento con pegaptanib sódico, Macugen, en DMAE. Curso

de la APEC, Ciudad de México. México, September, 2005.

10.2.167.

Main Lecture of the 81 Meeting of the Spanish Society of

Ophthalmology: Degeneración Macular Asociada a la Edad”. 81 reunión de la Soc. Esp. Oftalmología. Zaragoza, September, 2005.

10.2.168.

Lo mejor de la reunión de ARVO, 81 reunión de la Soc. Esp.

Oftalmología, Zaragoza, September, 2005

10.2.169.

Update in Macugen. 81 reunión de la Soc. Esp. Oftalmología.

Zaragoza, September, 2005.

10.2.170.

Macugen and Neovascular AMD. VISION Trials. 2 year data.

EVER 2005. European Association for Vision and Eye Research. Vilamoura, Portugal October 5-8, 2005.

10.2.171.

Que cal retenir dels Assaigs Clínics de DMAE. Societat Catalana

d’Oftalmologia. Catalunya, November 24-25, 2005

10.2.172.

Macugen

for

CNV/

AMD.

Ocular

Pharmacology

and

Therapeutics (ISOPT). Berlin, March 30-April 2, 2006.

10.2.173.

Macugen for DME Ocular Pharmacology and Therapeutics

(ISOPT). Berlin, March 30-April 2, 2006.

10.2.174.

Co-chair session Macular edema. Ocular Pharmacology and

Therapeutics (ISOPT). Berlin, March 30-April 2, 2006.

10.2.175.

Macugen World Wide Advisory Board Meeting. Fort Lauderdale,

May 5-6, 2006.

C. Vitae Jordi Monés 61

10.2.176.

J. Mones, J. Lotery, J. Pauleikhoff, G. Soubrane, A. Cruess, G.

Zlateva. Humanistic burden and health resource utilitsation among neovascular age-related macular degeneration (AMD) patients: Results from a multi-country cross-sectional study Euretina Congress. Lisbon, May 18-21, 2006.

10.2.177.

D. Pauleikhoff, J. Lotery, J. Mones, G. Soubrane, A. Cruess, G.

Zlateva, GERMANY. Impact of neovascular age-related macular degeneration on medical status, daily living and health resource utilisation: A survey of five countries Euretina Congress. Lisbon May 18-21, 2006.

10.2.178.

Chair Session Free Papers New Therapies on AMD. Euretina

Congress. Lisbon May 18-21, 2006.

10.2.179.

J.

Mones,

Two-year

efficacy

results

from

MARINA,

a

randomized, controlled, Phase III study of ranibizumab for minimally classic or occult choroidal neovascularization secondary to AMD Euretina Congress. Lisbon May 18-21, 2006.

10.2.180.

Curso

de

Avances

e

Innovaciones

en

Oftalmología.

Ranibizumab y Bevacizumab en el tratamiento de la DMAE exudativa. Barcelona, June 1-2, 2006.

10.2.181.

Tratamiento de la DMAE exudativa mediante Bevacizumab.

Resultados a 6 meses. Comunicación libre. Congreso de la Sociedad Española de Oftalmología A Coruña, Septiembre 27-30, 2006.

10.2.182.

Resultados del Ensayo Marina a 2 años de Ranibizumab

C. Vitae Jordi Monés 62

(Lucentis®) intravítreo para el tratamiento de las lesiones ocultas y mínimamente clásicas secundarias a DMAE exudativa. Congreso de la Sociedad Española de Oftalmología A Coruña,

September 27-30,

2006.

10.2.183.

Resultados del Ensayo Anchor a un año comparando la eficacia

del tratamiento de la DMAE exudativa con Ranibizumab (Lucentis®) y de la Terapia Fotodinámica. Comunicación de Investigación. Congreso de la Sociedad Española de Oftalmología A Coruña, September 27302006 10.2.184.

Hallazgos de Marina y Anchor: Tratamiento de membranas

ocultas y clásicas subfoveales Dr. Jordi Mones Carilla. Symposium ANTIANGIOGÉNICOS: LLEGA LA NUEVA ERA 82 Congreso de la Sociedad Española de Oftalmología A Coruña, September 27-30, 2006

10.2.185.

Directores Curso: Francisco Gómez-Ulla, Jordi Mones. TERAPIA

ANTIANGIOGÉNICA EN PATOLOGÍA DE LA RETINA Colaboradores: José M. Ruiz Moreno, Luis Arias, Máximo Abraldes, Maribel Fernández, Joaquín

Marticorena.

Congreso

de

la

Sociedad

Española

de

Oftalmología A Coruña, September 27-30,2006

10.2.186.

Bevacizumab en DMAE exudativa. Curso AVANCES EN EL

TRATAMIENTO

MEDICO

QUIRURGICO

DE

LA

PATALOGIA

MACULAR. Congreso de la Sociedad Española de Oftalmología A Coruña, September 27-30, 2006

10.2.187.

Quantification of improvements in visual acuity following

treatment with intravitreal ranibizumab in patients with CNV secondary to AMD in the Anchor and Marina Trials. Retina Society – Club Jules

C. Vitae Jordi Monés 63

Gonin Meeting. Cape Town, South Africa. October 16-20, 2006.

10.2.188.

Tratamiento de la DMAE exudativa mediante Bevacizumab.

Resultados a 6 meses. Curso DMAE; Hospital Germans Trias i Pujol. Catalunya, November 3, 2006.

10.2.189.

Management of AMD. Breakfast for Experts. American Academy

of Ophthalmology and Macula Society. American Academy of Ophthalmology Meeting. Las Vegas, November 13, 2006.

10.2.190.

Vision improvement as the new “gold standard” of care in AMD.

Looking forward in AMD > A new era in AMD treatment. Rome, March, 2007.

10.2.191.

Advisory Board Allergan. Rome, March, 2007.

10.2.192.

¿Es avastin el hermano pobre de lucentis? I Simposium sobre

Controversias en Oftalmología. Hospital de Bellvitge. Barcelona, March, 2007.

10.2.193.

Update lucentis. New Therapies for AMD. 7th Euretina

Congress. Montecarlo, May, 2007.

10.2.194.

Against PDT still has a major role in the treatment of ARMD.

Amsterdam Retinal Debate. 7th Euretina Congress. Montecarlo, May, 2007.

10.2.195.

Quantification of VA improvements Over Two Years in the

MARINA and ANCHOR Studies of Intravitreal Ranibizumab. Free papers. 7th Euretina Congress. Montecarlo May 2007

C. Vitae Jordi Monés 64

10.2.196.

Antiangiogénicos. II Curso de Actualización de Retina y Vitreo.

Oviedo, May, 2007.

10.2.197.

La mejoría de la visión debe ser el nuevo estándar terapéutico

en la DMAE. Curso Actualización DMAE. Sitges, May, 2007.

10.2.198.

Quantification of VA improvements Over Two Years in the

MARINA and ANCHOR Studies of Intravitreal Ranibizumab 0,3mg 0,5 mg for CNV secondary to AMD. Free papers. The Macula Society. London June, 2007.

10.2.199.

Mystery Case. Fluorescein cases for 2007.The Macula Society.

London, June, 2007

10.2.200.

Actualización en DMAE Directores: Jordi Monés i Carilla,

Francisco Gómez-Ulla de Irazazábal Nivel: Avanzado. 83 Congreso de la Sociedad Española de Oftalmologia. Las Palmas de Gran Canaria, September 26-29 , 2007.

10.2.201.

Simposium UNA NUEVA VISIÓN DE LA DMAE. Dr. Jordi

Monés:

Eficacia.

83

Congreso

de

la

Sociedad

Española

de

Oftalmologia, Las Palmas de Gran Canaria, September 26-29, 2007.

10.2.202.

Ranibizumab for myopic choroidal neovascularization. The 7th

International Symposium on Ocular Pharmacology & Therapeutics. February 28 -March 3, 2008.

10.2.203.

Avastin

for

proliferative

Diabetic

Retinopathy.

The

7th

International Symposium on Ocular Pharmacology & Therapeutics. February 28- March 3, 2008.

C. Vitae Jordi Monés 65

10.2.204.

Comunicación invitada: Aplicaciones Clínicas OCT Fourier

Domain. XII Congreso de la Sociedad Española de Retina y Vítreo. Zaragoza, March 8, 2008.

10.2.205.

Conferencia

invitada:

Aplicaciones

Clínicas

Domain. Reunió International Meeting Topcon.

OCT

Fourier

Sevilla, March 14,

2008.

10.2.206.

Efectos adversos anti VEGF BARRAQUER,

Curso Instituto

Barraquer, Barcelona, April 2008

10.2.207.

La

Ceguera

Evitable,

DMAE

y

Retinopatia

diabética.b

Cuadernos Diálogos para la Salud, Centro Médico Teknon. April 18, 2008

10.2.208.

Pro Neuroprotection. Implications of curretn treaments. Allergan

advisory board. Annual Meeting Association for Reasearch in vision and ophthalmology. Fort Lauderdale, USA. May 1-5, 2008

10.2.209.

Tractament actual de la degeneració macular associada a l’edat.

Conferencia Escola Optica Girona. Girona, May 8, 2008

10.2.210.

Tractament actual de la degeneració macular associada a l’edat.

Col·legi d’òptics de Lleida. Lleida, May 22, 2008

10.2.211.

Ranibizumab en neovascularización coroidea BARRAQUER

Curs Barraquer. Barcelona, May 16, 2008

10.2.212.

Avastin in Proliferative Diabetic Retinopathy. Primer Encuentro

de Retina Quirúrgica. Menorca, June 13-14, 2008.

C. Vitae Jordi Monés 66

10.2.213.

Tractament actual de la degeneració macular associada a l’edat.

Conferència Col.legi d’Òptics, Tarragona, July 16, 2008

10.2.214.

Ranibizumab en DMAE en regimen a demanda. 84 Congreso de

la Sociedad Española de Oftalmología. Sevilla, September 26, 2008

10.2.215.

Ranibizumab en MIOPIA. 84 Congreso de la Sociedad Española

de Oftalmología. Sevilla, September 26, 200

10.2.216.

DMAE i NVC. Clinica Juaneda. Palma de Mallorca, October

2008.

10.2.217.

Ceguesa Evitable. Càtedra Unesco. Dia internacional de la visió.

Escola d’Óptica de Terrassa. Terrassa, October 9, 2008.

10.2.218.

Searching for the optimal dosing. Current update (AMD). 8th

International AMD Congress. Firenze, October 17-18, 2008.

10.2.219.

Safety and tolerability of two dosing regimens of ranibizumab in

patients with subfoveal choroidal neovascularisation secondary to agerelated macular degeneration: EXCITE secondary outcomes. XXVIth Meeting Club Jules Gonin. St. Moritz, Switzerland. September 11-14, 2008.

10.2.220.

Member of Scientific Advisory Board. The 7th International

Symposium on Ocular Pharmacology & Therapeutics. February 28March3, 2008.

10.2.221.

Jordi Monés Conferència magistral, The Friedman’s lecture: “

AMD: From desperation to Hope. Massachusetts Eye and Ear Infirmary,

C. Vitae Jordi Monés 67

Harvard Medical School. Boston, Massachusetts, USA Febrer 18, 2009.

10.2.222.

Jordi Monés: DMAE y RANIBIZUMAB

deEgresadoOftalmología

centro

medico

nacional

Congreso bienal de

occidente.

Guadalajara, Mexico. March 5, 2009.

10.2.223.

Jordi Monés: DMAE y TERAPIA ANTI PDGF Congreso bienal

de EgresadoOftalmología centro medico nacional de occidente. Guadalajara, Mexico. March 5, 2009.

10.2.224.

Jordi Monés: DMAE y TERAPIA MONOCLONAL ANTI UNION

DE INTEGRINAS -‘FIBRONECTINA

Congreso bienal de Egresado

Oftalmología centro medico nacional de occidente. Guadalajara, Mexico. March 5 , 2009.

10.2.225.

Jordi

Monés,

Lluis

Arias

Vitrectomía

transconjuntival

microincisional + rtPA + SF6 + Avastin. Congreso bienal de Egresado Oftalmología centro medico nacional de occidente. Guadalajara, Mexico. March 5, 2009.

10.2.226.

Jordi Monés. ‘Current status of the examination and treatment of

diabetic

retinopathy’ L’Institute Cardiovasculare de Paris, Centro

Médico Teknon. Barcelona, March 13, 2009.

10.2.227.

Jordi Monés, Lluis Arias: Terapia anti PDGF combinada con anti

VEGF en DMAE exudativa. Congreso Sociedad Española de Retina Vitreo. Madrid March, 2009.

10.2.228.

Jordi Monés: Esport i Trauma Ocular. Acadeèmia de Ciències

Mèdiques de Catalunya i Balears, Centre d’Alt Rendiment de Sant Cugat. Barcelona, March 27, 2009.

C. Vitae Jordi Monés 68

10.2.229.

Jordi Monés, Samir Patel: Blocking Complement Factor 5 in

neovascular AMD: Phase I Study. 9th Euretina Congress. Nice, France. May 14-17, 2009.

10.2.230.

Jordi Monés: AMD Course, Dr Sobrane: Translating clinical

evidence into treatment guidelines: In the search of the optimal dosing. 9th Euretina Congress, Nice, France 14-17 may, 2009.

10.2.231.

Jordi Monés for the Ophthotech Anti-α5β1 Integrin in AMD Study

Group Interference of Cell Survival Signals by Targeting α5β1 Integrin (with Volociximab) and Vascular Endothelial Growth Factor in Subjects with Neovascular Age-related Macular Degeneration (AMD) – Results of a Phase 1 Study. SOE 2009, The 17th Congress of the European Society of ophthalmology, 13-16 june 2009

10.2.232.

Jordi Monés at the Reonet Novartis Advisory The 17th Congress

of the European Society of ophthalmology, 13-16 june 2009

10.2.233.

Jordi Monés at Eyesense Scientific Advisory Board. September

15th, Barcelona

10.2.234.

Jordi Monés, Nueva evidencia de ranibizumab en

DMAE

neovascular: Estudios SUSTAIN y EXCITE.SEO Sociedad Española de Oftalmologia, 24-25 september 2009, Santander.

10.2.235.

Jordi Monés, Lluis Arias, Marc Biarnés: Symposium Angelini.

DMAE seca: El nuevo reto. Sociedad Española de Oftalmologia, 24-25 september 2009, Santander

10.2.236.

Jordi Monés: Symposium OCT Spectralis: Avances en Técnicas

C. Vitae Jordi Monés 69

diagnósticas para la DMAE seca. Sociedad Española de Oftalmologia, 24-25 september 2009, Santander.

10.2.237.

Jordi Monés: Combined Inhibition of a5B1 Integrin and Vascular

Endothelial Growth Factor for Neovascular Age-Related Macular Degeneration – Phase 1 Study Retina Congress 2009 New York, september 29-0ct 4

10.2.238.

Jordi Monés at the ERAB Allergan Advisory Board Meeting. Sept

29, New York

10.2.239.

Jordi Monés: Potential Future Treatments for Neovascular AMD.

2009 International AMD and Retina Congress: Focusing of the issues of Today and looking to the future. 9-10 Oct, 2009.

10.2.240.

Jordi Monés at Meet with the Experts: safety of anti VEGF

treatments. 2009 International AMD and Retina Congress: Focusing of the issues of Today and looking to the future. 9-10 Oct, 2009.

10.2.241.

Jordi Monés at Meet with the Experts: Daibetic Macular Edema

and Retinal Vein Occlusion. 2009 International AMD and Retina Congress: Focusing of the issues of Today and looking to the future. 910 Oct, 2009.

10.2.242.

Jordi Monés at the Scientific Committee 2009 International AMD

and Retina Congress: Focusing of the issues of Today and looking to the future. 9-10 Oct, 2009.

10.2.243.

Jordi Monés “Phase III Study of Dexamethasone Drug Delivery

System in the Treatment of Macular Edema Due to Branch and Central Retinal Vein Occlusion” Reunión Allergan, Madrid 16 octubre 2009

C. Vitae Jordi Monés 70

10.2.244.

Jordi Monés at the ERAB Allergan Advisory Board Meeting,

Irvine, California USA, Oct 22

10.2.245.

Jordi Monés: Curso DMAE seca "El nuevo reto".40 Congrés de

la Societat Catalana d’Oftalmologia Barcelona, 19-21 Nov 2009

10.2.246.

Jordi Monés: Mesa Redonda Degeneración Macular Asociada a

la Edad: Nuevas perspectivas terapeúticas. 40 Congrés de la Societat Catalana d’Oftalmologia Barcelona, 19-21 Nov 2009

10.2.247.

Jordi Monés: OCT alta resolución y autofluorescencia en DMAE

seca. Curso Ultimas novedades para el tratamiento DMAE húmeda y DMAE seca. 40 Congrés de la Societat Catalana d’Oftalmologia Barcelona, 19-21 Nov 2009

10.2.248.

Jordi Monés: DMAE Exudativa y atrófica. Nuevos advances.

Ateneo de Madrid, Conferència Reunión –Colegio de Farmaceúticos. Madrid 24 nov 2009

10.2.249.

Jordi Monés: DMAE: 20 anys de viatge. Curs optics. Escola

òptica de Terrassa, 26 Nov 2009

10.2.250.

Jordi Monés Anti-VEGF for Atypical Indications. The 8th

International Symposium on Ocular Pharmacology and Therapeutics. Dec 3-6 2009, Rome Italy

10.2.251.

Jordi Monés 'Anti-VEGF for myopic CNV. The 8th International

Symposium on Ocular Pharmacology and Therapeutics. Dec 3-6 2009, Rome Italy

C. Vitae Jordi Monés 71

10.2.252. optical

Jordi Monés Imaging autofluorescence and high resolution coherent

tomography

.symposium

Heidelberg,

The

8th

International Symposium on Ocular Pharmacology and Therapeutics. Dec 3-6 2009, Rome Italy

10.2.253.

Jordi Monés Anti-C5 therapy in DRY AMD (Ophthotech) The 8th

International Symposium on Ocular Pharmacology and Therapeutics. Dec 3-6 2009, Rome Italy

10.2.254.

Jordi Monés, Nuevas perspectivas en el Tratamiento de la

DMAE seca. IV Symposium sobre controversias en Oftalmologia. Hospital de Bellvitge, Barcelona Feb 2010.

10.2.255.

Jordi Monés at the ERAB Allergan Advisory Board Meeting

Paris, France january 14, 2010

10.2.256.

Anti Complement C5 Therapy in DRY AMD: PHASE I CLINICAL

TRIAL 33rd Annual Macula Society meeting in Tucson, Arizona, Feb 24-27, 2010

10.2.257.

Terapia Anti Complemento C5 en DMAE SECA: ENSAYO FASE

I. Congreso Sociedad Española de Retina Vitreo, Santiago de Compostela, march 5-6, 2010

10.2.258.

DMAE seca: Nuevos avances. “Curso Formación Continuada

Instituto Barraquer: Diagnóstico y tratamiento de las afecciones de la Mácula. Barcelona, April 16, 2010.

10.2.259.

Jordi Monés Jordi Monés Investigator Meeting for the Phase 2

Anti-PDGF Study (OPH1001) World Ophthalmology Congress, Berlin

C. Vitae Jordi Monés 72

June 4th 2010.

10.2.260.

Jordi

Monés

at

the

Reonet

Novartis

Advisory.

World

Ophthalmology Congress, Berlin June 9th 2010

10.2.261.

Avenços en el tractament de la DMAE exudativa i DMAE

atròfica. Conferència al Col.legi de Metges de Lleida. Lleida, June 7, 2010

10.2.262.

Nous tractaments en la DMAE. Conferència Col.legi d’Òptics de

Barcelona. Barcelona, June 30, 2010

10.2.263.

El tratamiento de las oclusiones venosas con un implante

intravítreo de dexamentasona (OZURDEX) Ponencia Oficial Congreso de la Sociedad Española de Oftalmología, Madrid September 2010

10.2.264.

Dry

AMD:

The

new

challenge.

Heidelberg

Spectralis

Symposium. Congreso de la Sociedad Española de Oftalmología, Madrid September 2010

10.2.265.

¿Cuándo dejar de tratar con anti VEGF? Symposium Novartis.

Congreso de la Sociedad Española de Oftalmología, Madrid September 2010

10.2.266.

Course and Wet lab on ozurdex application, Uppsala, Sweden

September 30, 2010

10.2.267.

ERAB Advisory Board on Retinal Vein Occlusion, Chicago,

October 17, 2010

10.2.268.

The Rationale of the Fusion Regimen of intravitreal ranibizumab

C. Vitae Jordi Monés 73

for exudative AMD. 10th International AMD and Retina Congress, Lugano, 29-30 October 2010 Switzerland.

10.2.269.

Chairing Session on Management of Neovascular AMD - Current

therapy and future options, 29 October. Speakers Frank Holz (Germany), Paolo Lanzetta (Italy), José Cunha-Vaz (Portugal) Peter Kaiser (USA) 10th International AMD and Retina Congress, Lugano, 29-30 October 2010 Switzerland.

10.2.270.

Avenços en el Tractament de la DMAE. Escola Universitaria de

Óptica y Optometría de Terrassa, November 26, 2010

10.2.271.

5th EVICR.net Members Meeting- London, 15/16 November

2010

10.2.272.

Meeting of the AMD and Retinal Dystrophies Expert Committee

of the European Vision Clinical Research Netwwork (EVICR.net) London, 15/16 November 2010

10.2.273.

Reunión Comité Asesor para Eylea® (VEGF-Trap eye) Bayer

Schering Pharma Barcelona, November 20, 2011

10.2.274.

DMAE atrófica. Perspectivas presentes y futuras de tratamiento.

Dr. Jordi Monés (Barcelona) Santa Lucia 2010. Sociedad Oftalmológica de la Comunidad Valenciana, Valencia, December 13, 2010

10.2.275.

Region Europe Ophthalmics Network (REONET) advisory board

meeting in Paris, France, on 13th January 2011

10.2.276.

Meeting of the European writing Committee of the European

guidelines for the treatment of the macular edema secondary to retinal

C. Vitae Jordi Monés 74

vein occlusion. Paris, January 13, 2011

10.2.277.

ERAB Advisory Board on Retinal Vein Occlusion, Paris January

15, 2011

10.2.278.

Lecture "El nou pas en la DMAE exudativa" Col-legi Oficial

d’Optics i Optometristes de Catalunya, Barcelona, january 24, 2011

10.2.279.

Lecture "Esport i trauma ocular ". Col-legi Oficial d’Optics i

Optometristes de Catalunya, Barcelona, january 24, 2011

10.2.280.

2011 Eylea Advisory Board Meeting on VEGF Trap, Bayer.

Miami,February 13, 2011

10.2.281.

Dispositivos intravitreos de liberación corticoides en edema

macular diabètico", Symposium Vitreo Retina, Bausch and Lomb, Museo Reina Sofia, Madrid March 3, 2011

10.2.282.

Member of the Local Advisory Board

of The 2nd World

Congress on Controversies in Ophthalmology (COPHy), Barcelona, Spain, March 3-6, 2011

10.2.283.

Debate: Is SD-OCT necessary and sufficient to guide clinical

decisions in neovascular AMD or diabetic macular edema? Yes U. Schmidt-Erfurth, Austria No J Mones Spain The 2nd World Congress on Controversies in Ophthalmology (COPHy) Barcelona, Spain, March 3-6, 2011

10.2.284.

Debate: Is SD-OCT necessary and sufficient to guide clinical

decisions in neovascular AMD or diabetic macular edema? Yes U. Schmidt-Erfurth, Austria No J Mones Spain The 2nd World Congress

C. Vitae Jordi Monés 75

on Controversies in Ophthalmology (COPHy) Barcelona, Spain, March 3-6, 2011

10.2.285.

Jordi Monés, Moderator of the Round Table Management of

Retinal Vein Occlusion The 2nd World Congress on Controversies in Ophthalmology (COPHy) Barcelona, Spain, March 3-6, 2011

10.2.286.

Ophthotech Advisory Board ARVO Meeting, Fort Lauderdale

May 2, 2011

10.2.287.

ERAB Advisory Board on Retinal Vein Occlusion, ARVO

Meeting, Fort Lauderdale May 3, 2011

10.2.288.

Iluvean Allimera Advisory Board Euretina Meeting. London UK

May 25 2011

10.2.289.

2nd 2011 Eylea Advisory Board Meeting on VEGF Trap, Bayer.

Euretina Meeting. London UK, May 27, 2011

10.2.290.

Novartis Advisory Board Euretina Meeting. London UK, May 28,

2011

10.2.291.

ERAB Advisory Board on Retinal Vein Occlusion, Euretina

Meeting. London UK, May 29, 2011

10.2.292.

Análisis de los resultados del Estudios CATT e IVAN Día de la

Subespecialidad. Congreso de la Sociedad Española de Oftalmología, Oviedo SPAIN, 21 Sept, 2011

10.2.293.

Hyporreflective wedge in geographic atrophy secondary to AMD.

Un under-reported finding. Reunión Expertos y Junta de la Sociedad

C. Vitae Jordi Monés 76

Española de Retina Vitreo. Congreso de la Sociedad Española de Oftalmología, Oviedo, SPAIN 21 Sept, 2011

10.2.294.

Nuevos hallazgos mediante OCT spectral domain en DMAE

atrófica. Symposium Bloss, Congreso de la Sociedad Española de Oftalmología, Oviedo, SPAIN 22 Sept, 2011

10.2.295.

Eficacia y seguridad. Resultados del estudio CATT. Congreso de

la Sociedad Española de Oftalmología, Oviedo, SPAIN 22 Sept, 2011

10.2.296.

Algoritmos de tratamiento de las oclusiones venosas de retina.

Simposium

Allergan.

Congreso

de

la

Sociedad

Española

de

Oftalmología, Oviedo, SPAIN 22 Sept, 2011

10.2.297.

Camp Nou Sense Fum. Assemblea de Socis Compromisaris del

Futbol Club Barcelona, 24 sept, 2011.

10.2.298.

Does foveal swelling exist in foveal sparing of geographic

atrophy secondary to AMD?. Spectralis Meeting. Edimburg, UK 1 Oct 2011

10.2.299.

The Rationale for the FUSION regimen in exudative AMD.

Spectralis Meeting. Edimburg, UK 1 Oct 2011

10.2.300.

The FUSION regimen. Novartis Advisory Board. American

Academy of Ophthalmology. Orlando, 20 Oct, 2011.

10.2.301.

Intravitreal safety delivery: Meet the experts 11 international

AMD and Retina Congres, lisbon 4-5 nov 2011

10.2.302.

Ocular

neovacularization

in

RVO

Meet

the

experts

11

C. Vitae Jordi Monés 77

international AMD and Retina Congres, lisbon 4-5 nov 2011

10.2.303.

International Expert Summit. The Angiogenesis Foundation.

Berlin, 14-15 nov 2011

10.2.304.

Steering Committee meeting of Crystal and Bravo Trial for RVO.

Prague, 17 nov,2011

10.2.305.

Prohibited Treatments during the Chrystal and Brighter Trials.

Investigator Meeting, Prague, 17 nov,2011

10.2.306.

Endpoints

in

Crystal

and

Brighter

Trials.

Investigator

Meeting, Prague, 17 nov,2011

10.2.307.

Utilidad de los anti VEGF en oclusión venosa de la retina. III

Jornadas Vitreo Retina Canarias (VCR). Puerto de la Cruz, 26 Nov, 2011.

10.2.308.

Targeting Anti Complement anti C5 therapy for geographic

atrophy secondary to age-related macular degeneration. A phase I study. International Symposium of Pharmacology and Therapeutics. Vienna, Dec 1-4, 2011

10.2.309.

Chair of Dry AMD and Free Paper Session. International

Symposium of Pharmacology and Therapeutics. Vienna, Dec 1-4, 2011

10.2.310.

ICG silent polypoidal vasculopathy with favourable response to

thermal laser therapy. Wet AMD Panel. Case Presentation and Discussion.

International

Symposium

Therapeutics. Vienna, Dec 1-4, 2011

of

Pharmacology

and

C. Vitae Jordi Monés 78

10.2.311.

Chair of Wet AMD II and Free Paper Session. International

Symposium of Pharmacology and Therapeutics. Vienna, Dec 1-4, 2011

10.2.312.

Targeting platelet Derived (PDGF) and vascular endothelial

(VEGF) growth factors for neovascular AMD. Phase I and Phase II. International Symposium of Pharmacology and Therapeutics. Vienna, Dec 1-4, 2011

10.2.313.

Fusion Regimen for Ranibizumab; combination of OCT guided

retreatment with fixed retreatment. (PRN+FIXED) for wet AMD. International Symposium of Pharmacology and Therapeutics. Vienna, Dec 1-4, 2011

10.2.314.

ERAB Advisory Board Meeting on Retinal Vein Occlusion,

International Symposium of Pharmacology and Therapeutics. Vienna, Dec 1-4, 2011

10.2.315.

Jordi Monés, RVO expert panel meeting. Rome, 29th January

2012

10.2.316.

Iluvean Allimera Advisory Board Meeting. WOC, Abu Dhabi,

UAE February 17, 2012

10.2.317.

Region Europe Ophthalmics Network (REONET) advisory board

meeting. Valencia, Spain, March 1, 2012

10.2.318.

Jordi Monés, Líneas de Investigación en la DMAE atrófica.

Programa de Postgrado Diagnóstico y tratamiento de las afecciones de la mácula. Institut Univeristari Barraquer. Barcelona. March 16, 2012

C. Vitae Jordi Monés 79

10.2.319.

Discussion: People with large drusen in both eyes are at

increased risk of progressing to choroidal neovascularization or geographic atrophy or both following cataract surgery. Yes Y. Durlu, Turkey No J Mones, Spain . The 3rd World Congress on Controversies in Ophthalmology (COPHy) Istanbul, Turkey, March 22-25, 2012

10.2.320.

Jordi Monés, Iluvien or Ozurdex. The 3rd World Congress

on Controversies in Ophthalmology (COPHy) Istanbul, Turkey, March 22-25, 2012

10.2.321.

Jordi Monés, Moderator of the Round Table Management of

Macular Edema from Retinal Vein Occlusions. The 3rd World Congress on Controversies in Ophthalmology (COPHy) Istanbul, Turkey, March 22-25, 2012

10.2.322.

Jordi Monés, Inflammation and ME. Aria workshop. Enlighten

meeting, Barcelona, Spain, April 14th 2012

10.2.323.

Jordi Monés, Clinical signs and characteristics: how to recognize

inflammation in clinical practice. Aria workshop. Enlighten meeting, Barcelona, Spain, April 14, 2012.

10.2.324.

Jordi Monés, moderador, Seguridad sistémica de los fármacos

de uso intravítreo. Actualización de las terapias intravítreas con fármacos Anti – VEGF Novartis. Barcelona, Spain, April 26, 2012 10.2.325.

Jordi Monés, Moderator Poster Session 547. AMD Clinical

Research VII Jordi M. Monés. Centro Medico Teknon, Institut de la Màcula i de la Retina, Barcelona, Spain. May 10, 2012 ARVO Meeting, Fort Lauderdale, Florida, USA 10.2.326.

6530/A532 - Hyporeflective Wedge-Shaped Band in Geographic

C. Vitae Jordi Monés 80

Atrophy Secondary to Age-Related Macular Degeneration: An Underreported Finding Jordi M. Mones, Marc Biarnes, Fabio M. Trindade. Centro Medico Teknon, Institut de la Màcula i de la Retina, Poster Session 547. AMD Clinical Research VII Barcelona, May 10, 2012 10.2.327.

6531/A533 - Optical Coherence Tomography Characterization of

Apparent Foveal Swelling in Patients with Foveal Sparing Secondary to Geographic Atrophy. Fabio M. Trindade, Jordi Mones, Marc Biarnes. Institut de la Màcula i de la Retina, Barcelona, Spain. Poster Session 547. AMD Clinical Research VII Barcelona, May 10, 2012 10.2.328.

6532/A534

-

Reproducibility

of

Fundus

Autofluorescence

Patterns in Geographic Atrophy Secondary to Age-Related Macular Degeneration. Marc Biarnes, Jordi Mones, Fabio M. Trindade. Institut de la Màcula i de la Retina, Barcelona, Spain. Poster Session 547. AMD Clinical Research VII. Barcelona, May 10, 2012 10.2.329.

Jordi Monés, Evaluation of 2-year CATT and 1-year IVAN

results. Novartis Canada Ophthalmology Advisory Board Meeting - Fort Lauderdale, FL. Canada, May 7, 2012. 10.2.330.

Jordi Monés, Intravitreal Expert Group HFMEA Review Meeting

Fort Lauderdale, Florida, USA. May 5, 2012 10.2.331.

Jordi Monés, AMD experts group New trial discussion. Bayer

Meeting, Fort Lauderdale, Florida, USA. May 8, 2012 10.2.332.

Jordi Monés, Conferència “Barça sense fum: l’èxit d’una

iniciativa pionera”, Jornada “Día mundial sin tabaco”, Centro Médico Teknon. Barcelona, May 31, 2012 10.2.333.

Jordi Monés, Fusion regimen: ranibizumab in treatment naive

patients with exudative age-related macular degeneration and high visual acuity. XXVIIIth Meeting of the Club Jules Gonin. Reykjavik, Iceland, June 20- 23, 2012

C. Vitae Jordi Monés 81

10.2.334.

Campaign Presentation: "Quit Smoking with Barça" with the

participation of John DALLI, Member of the EC in charge of Health and Consumer Policy; Sandro ROSELL, President of FC Barcelona and Jordi MONES i CARILLA, Medical Director of FC Barcelona. September 18, 2012. 10.2.335.

Speaker training Eylea. Bayer. Dr. Jordi Monés, member of the

Steering Committee. Berlin, September 24, 2012. 10.2.336.

Vitreo-retina (Paneles 001 al 013). Dres. Ramón TORRES y

Jordi MONÉS. 88 Congreso de la Sociedad Española de Oftalmología. Barcelona, September 27, 2012 10.2.337.

Simposium: Controversias en retina. Panel de Discusión DMAE:

¿Es necesario el seguimiento mensual en DMAE? Extensión de los periodos de seguimiento. Dr. Jordi Monés . 88 Congreso de la Sociedad Española de Oftalmología. Barcelona, September 27, 2012. 10.2.338.

Mesa: Terapia proactiva - cambiando el abordaje actual en el

tratamiento de la DMAE. Tratamiento proactivo: Siguiente paso en el abordaje de la DMAE. Individualizar el tratamiento proactivo. Dr. Jordi Monés. 88 Congreso de la Sociedad Española de Oftalmología. Barcelona, September 28, 2012. 10.2.339.

Presentación: Nuevo hallazgo en las capas de la retina de

pacientes con atrofia geográfica secundaria. Dr. Jordi Monés. II Reunión de Expertos en Retina Heidelberg. Barcelona. September 27, 2012. 10.2.340.

Round table discussion: Are EU citizens health literate and

aware of healthy lifestyles? Dr. Jordi Monés. 15th European Health Forum Gastein. European Comission. Brusel•les. October 3-6, 2012. 10.2.341.

Institutional opening speech: IV Jornadas de MuscleTech

Network. Dr. Jordi Monés. Barcelona, October, 2012.

C. Vitae Jordi Monés 82

10.2.342.

Conferencia: Degeneración macular asociada a la edad (DMAE).

Dr. Jordi Monés. Associació Discapacitat Visual Catalunya. Barcelona. October, 2012. 10.2.343.

Inaugurazione ufficiale LETTURA MAGISTRALE: In the search

for the optimal regimen and new perspectives in the treatment of AMD. J. Monés. 3° Congresso Nazionale dell`Associazione Italiana Medici Oculisti. October 26, 2012. 10.2.344.

Meet the expert session. Anti-VEGF therapy in other retinal

diseases (excluding AMD, DR and RVO) The management of myopic CNV. Jordi Monés and Paolo Lanzetta. 12th International AMD and Retina Congress. Prague. November 2, 2012. 10.2.345.

Session: The management of neovascular AMD. Interactive

clinical case 4: Treatment of RAP in the anti-VEGF era. Dr. Jordi Monés. 12th International AMD and Retina Congress. Prague. November 3, 2012. 10.2.346.

Conferencia inaugural: Barça sin humo y Quit Smoking with

Barça: por unos corazones con futuro. V Congreso Clínico semFYC en Cardiovascular. Barcelona, November 22, 2012. 10.2.347.

Taula rodona: Retina mèdica. DMAE seca. Dr. Jordi Monés. 43è

Congrés de la Societat Catalana d’Oftalmologia. Barcelona, November 30, 2012. 10.2.348.

Conferencia: Líneas de Investigación de la Barcelona Macula

Foundation. Dr. Jordi Monés. A.A.R.P.C. Seu de l’ONCE. Barcelona. December 1, 2012. 10.2.349.

Edema Macular Diabetic. Allergan Advisory Board Meeting.

Barcelona. December 2, 2012. 10.2.350.

Actualización en el manejo de la DMAE y el Edema macular. A

cargo del Dr. Jordi Monés. Curso a cargo de la Delegación de Islas

C. Vitae Jordi Monés 83

Baleares del Colegio Nacional de Ópticos –Optometristas de España (CNOO). Mallorca. December 15, 2012. 10.2.351.

Ex-smokers are unstoppable. "Quit Smoking with Barça". A

cargo del Dr. J. Monés. Delivering success stories in public health for EU citizens. EU Health Prize for Journalists 2012. European Comission. Brussels. January 30, 2013. 10.2.352.

La experiencia de la campaña "Quit Smoking with Barça". Dr.

Jordi Monés.: IIIas Jornadas de la SCATT. CaixaForum, Barcelona. February 08, 2013. 10.2.353.

Dry AMD. The Complement System in Dry AMD: a Therapeutic

Target.

Dr.

Jordi

Monés.

International

Symposium

on

Ocular

Pharmacology and Therapeutics (10TH ISOPT Clinical). March 08, 2013. 10.2.354.

Wet AMD. Combination Therapy Targeting VEGF and PDGF for

Wet AMD by Jordi Mones. International Symposium on Ocular Pharmacology and Therapeutics (10TH ISOPT Clinical). Paris. March 09, 2013. 10.2.355.

Wet AMD. Case Discussion/Wet AMD Panel. Panel: Paulo

Lanzetta, Italy, Jordi Mones, Spain, Gisele Soubrane, France & Pravin Dugel, USA. International Symposium on Ocular Pharmacology and Therapeutics (10TH ISOPT Clinical). Paris. March 09, 2013. 10.2.356.

Tobacco Control, Smoking Cessation and Sports Stadia.

Establishing a Club-Led ‘Smokefree Stadia Policy’ for Camp Nou by Dr. Mones. European Healthy Stadia Conference 2013. Manchester City FC. March 21st, 2013. 10.2.357.

Debate: Management of center-involved DME and 20/50 in

pseudophake?

Anti-VEGF

by

J.

Mones.

World

Congress

on

Controversies in Ophthalmology (COPHy). Budapest. April 04-07, 2013.

C. Vitae Jordi Monés 84

10.2.358. extend

Debate: Which regimen: PRN vs. Fixed regimen? Treat and by

J.

Mones.

World

Congress

on

Controversies

in

Ophthalmology (COPHy). Budapest. April 04-07, 2013. 10.2.359.

AVANCES EN DMAE Coordinadores: Jordi Monés (España),

Lihteh Wu (Costa Rica), Virgil Alfaro (EEUU). Caracterización de hallazgos foveales y velocidad de progresión de la atrofia geográfica. Jordi Monés. XXI Curso Panamericano. Galicia. April 27, 2013. 10.2.360.

Guest speaker. Novartis Canada Regional Consult Panel.

Vancouver, British Columbia. May, 4th, 2013. 10.2.361.

Novartis Scientific Experts Forum ‘Sharing experience in wet

AMD: real choices for real patients?. “The optimization of anti-VEGF dosing regimens” Jordi Monés. 2013 ARVO Annual Meeting. Seattle, Washington. May 5th – 8th, 2013. 10.2.362.

Assessment of linearity of growth in time in geographic atrophy

secondary to age-related macular degeneration. 6298 Poster Board Number: D0114. Jordi M. Mones, Marc Biarnes. 2013 ARVO Annual Meeting. Seattle, Washington. May 5th – 8th, 2013. 10.2.363.

Main Session: Dry AMD. Characterization of retinal layers in

foveal sparing secondary to gepgraphic atrophy by Jordi Monés. 13th EURETINA Congress. Hamburg, Germany. September 26th-29th, 2013. 10.2.364.

REONET Advisory Board. NOVARTIS. Amsterdam. October 4th,

2013. 10.2.365.

Curso de actualización en investigación sobre enfermedades

raras: distrofias de la retina. Distrofias de la retina: Diagnóstico, tratamiento y seguimiento de los pacientes. Dr. Jordi Mones. IIS-FJD Catedra Bidons Egara CIBERER y CIBER BBN. Universidad Miguel Hernandez. Madrid, España. Octubre 9, 2013.

C. Vitae Jordi Monés 85

10.2.366.

EVICR.net Expert Committees. AMD and retinal distrophies.

Coordinator: Jose Sahel, MD, PhD. Members: Rufino Silva, Bart Leroy, Adnan Tufail, Frank Holz, Jordi Monés, Ugo Introini. Co-opted Member: Carel Hoyng. The EVICR.net Annual Meeting. Paris, France. October 14-15th, 2013. 10.2.367.

Institutional

opening

speeches

Jordi

Monés,

FCB.

5th

th

MuscleTech Network Workshop. Barcelona, Spain. October 14 -15th, 2013. 10.2.368.

ROCHE SYMPOSIUM. Dr. Jordi Monés. 13th International AMD

& Retina Congress. Londres, England. October 24th, 2013. 10.2.369.

13th International AMD and Retina Congress. The Long-Term

Management of AMD: Efficacy, Safety and Economic Considerations. Keypad case presentations Sobha Sivaprasad, UK; Jean-Francois Korobelnik, France; Jordi Monés, Spain; Rafael Navarro, Spain. Panel Discusion. 25th October 2013. Dublin, Ireland. 10.2.370.

ESASO Style Debates and ESASO Master Classes. Sessions

concurrent: Delegates to attend one session from the choice below. Master Class 2: New imaging techniques: Instrumentation for visualizing the instruments of vision. Emin Ozmert, Turkey Jordi Monés, Spain. 13th International AMD and Retina Congress. Dublin, Ireland. October 25th, 2013. 10.2.371.

Avenços en el tractament de la degeneració macular i altres

malalties de la retina. Dr. Jordi Monés. Fundació Josep Palau Francas. Ripoll, España. Novembre 12, 2013. 10.2.372.

Advisory Board Novartis. AAO Annual Meeting. New Orleans.

November 16th- 19th, 2013. 10.2.373.

Advisory Board Alcon. AAO Annual Meeting. New Orleans.

November 16th- 19th, 2013.

C. Vitae Jordi Monés 86

10.2.374.

Simposi Bayer. Dr. Jordi Monés. 44è Congrés de la Societat

Catalana d'Oftalmologia (SCO). Barcelona, Espanya. Novembre 28-30, 2013. 10.2.375.

Líneas de investigación en la DMAE atrófica. Dr. Jordi Monés.

Diagnóstico y tratamiento delas afeccionesde la mácula. Programa de Postgrado. Institut Universitari Barraquer. Barcelona, Espanya. 14 de febrero de 2014 10.2.376.

Subtle details in inclusion criteria may be the key for success of

clinical trials for chronic conditions. Speaker: Dr. Jordi Monés. GLOBAL HEALTH VISION LECTURE SERIES. Sponsor: National Eye Institute (NEI). Co-sponsors: Fogarty International Center (FIC) AND NIH Global Health Interest Group (GHIG). National Institutes of Health (NIH) Main Campus, Bethesda, MD. February 19, 2014. 10.2.377.

SESSION I. Dry AMD. Impact of a Lesion Size-Derived

Classification of Geographic Atrophy in Progression Rate. Moderator and speaker: Jordi Monés. 37th Annual Scientific Program, Macula Society 2014. Key Largo, Florida. February 20, 2014. 10.2.378.

Mesa Redonda: Manejo de la terapia intraocular. Criterios de

importancia en el manejo terapéutico de la DMAE atrófica. Jordi Mones. XVIII Congreso De La Sociedad Española De Retina Y Vítreo. Sevilla, Spain. March 7-8, 2014. 10.2.379.

Poster: Comparación entre luz azul, infrarrojo y multicolor en la

identificación de las drusas reticulares. Dr. Hussein Almuhtaseb, Dr. Josep Badal MD, Marc Biarnés O.D., M.P.H. Dr. Jordi Monés MD, PhD. XVIII Congreso De La Sociedad Española De Retina Y Vítreo. Sevilla, Spain. March 7-8, 2014. 10.2.380.

Vision Research Day. Novartis Ophthalmic and Alcon. Zürich,

Switzerland. March 14-15, 2014

C. Vitae Jordi Monés 87

10.2.381.

Retinnova. 7 años en la nueva era by Dr. Jordi Monés

(Chairman Retinnova). Novartis. Madrid, Spain. March 28-29, 2014. 10.2.382.

“II Guardons contra el càncer”'. Associació Espanyola Contra el

Càncer (Aecc). Dr. Jordi Monés, Responsible of the Medical and Sport Performance Department of Futbol Club Barcelona, recull el Premi en representació del FCBarcelona. Barcelona, Spain. April 2, 2014. 10.2.383.

Advisory Board de Bayer. Barcelona, Spain. April 24, 2014.

10.2.384.

Advisory Board de Novartis. Madrid, Spain. May 25, 2014.

10.2.385.

IV Curso de Actualización en Retina y Vítreo. DMAE no

exudativa y Curso de casos clínicos. Dr. Jordi Monés. Instituto Oftalmológico Fernández-Vega de Oviedo, Spain. May 23-24, 2014. 10.2.386.

Advisory Board de Roche. London, September 10, 2014.

10.2.387.

Advisory Board de Teva. London, September 11, 2014.

10.2.388.

Advisory Board de Eylea. London, September 11, 2014.

10.2.389.

Advisory Board de Roche. Lampalizumab. London., September

11, 2014. 10.2.390.

14th Euretina Congress. “Ranibizumab: Expanding Horizons in

RVO Management” & “What does early neovascular AMD look like?”. Dr. Jordi Monés, Chaiman and speaker. Novartis. London, September 11-14, 2014. 10.2.391.

14th

Euretina

Congress.

“Performance

characteristics

of

multicolour versus blue light and infrared imaging in the identification of reticular pseudodrusen” Dr. H. Almuhtaseb, Dr. J. Badal, Dr. M. Biarnés and Dr. Monés. London, September 11-14, 2014. 10.2.392.

14th

Euretina

Congress.

Session:

“Individually

dosed

ranibizumab, alone or combined with laser, versus laser alone in branch

C. Vitae Jordi Monés 88

retinal vein occlusion patients with visual impairment due to macular edema- 6 month results of the BRIGHTER study”. Dr. Monés together with

M. Larsen, F. Boscia, H. Gerding, I. Pearce, S. Priglinger, R.

Tadayoni, M. Gekkieva and A. Lotery. London, September 11-14, 2014. 10.2.393.

14th Euretina Congress. Session “Efficacy and safety of

ranibizumab 0.5 mg in patients with visual impairment due to macular edema secondary to central retinal vein occlusion- design and baseline characteristics of the CRYSTAL study”. Dr. Monés with P. Hykin, H. Gerding, F. Boscia, R. Tadayoni,S. Priglinger, I. Pearce, W. Stubbings, M. Gekkieva and A. Cole. London, September 11-14, 2014. 10.2.394.

Vitreoretinal

Society

(SERV)

Symposium

on

pathological

myopia: “Anti-VEGF therapy for choroidal neovascular membranes”. By Dr. Monés. London, September 11-14, 2014. 10.2.395.

Conference Choroideremia: knowledge and therapy. “The

classification and evolution of choroideremia and the structure of the retina in patients with the pathology” by Dr. Monés. Organised by Spanish Choroideremia Association with the collaboration of the University of the Basque Country. Vitoria, Spain. September 16-17, 2014 10.2.396.

Jornada

científico

divulgativa.

“Investigación

en

DMAE:

exudativa y atrófica. Ensayos Clínicos y pre-Clínicos.” Ponente: Dr. Monés. Asociación de miopía magna con retinopatías (AMIRES). Hospital Clínico de Madrid, Spain. Octubre 13, 2014. 10.2.397.

6th MuscleTech Network Workshop.

Institucional Opening

Speech. Dr. Jordi Monés. Centro Tecnológico Leitat, el FCBarcelona y Aspetar. Fútbol Club Barcelona. Barcelona, Spain. Octubre 13, 2014 10.2.398.

AAO Chicago Congress. Section VII: First-time Results of

Clinical Trials, Part I. PM BRIGHTER and CRYSTAL Studies Jordi M Mones MD. Chicago. October 17, 2014

C. Vitae Jordi Monés 89

10.2.399.

14th ESASO Retina Academy. MasterClass 2: Chorioretinal

dystrophies. Dr. Jordi Monés, Rafael Navarro. European School for Advanced Studies in Ophthalmology (ESASO). Istanbul, Turkey. November 14, 2014.

10.2.400.

14th ESASO Retina Academy. SESSION 4 Evidence-based

management of retinal ischaemia Dr. Jordi Monés. European School for Advanced Studies in Ophthalmology (ESASO). Istanbul, Turkey. November 14, 2014. 10.2.401.

14th ESASO Retina Academy. Retinamour Clinical Case

Discussion

(Medical)

Chair:

Lawrence

Yannuzzi,

USA.

Panel:

Christopher Brand, UK. Dr. Jordi Monés, Spain. European School for Advanced Studies in Ophthalmology (ESASO). Istanbul, Turkey. November 14, 2014. 10.2.402.

14th ESASO Retina Academy. SESSION 5 AMD Chairs: Ursula

Schmidt-Erfurth, Austria Marco Zarbin, USA. AMD clinical trials update Jordi Monés, Spain. European School for Advanced Studies in Ophthalmology (ESASO). Istanbul, Turkey. November 15, 2014. 10.2.403.

ENCUENTRO:

“Patologías

de

la

Retina”.

Principales

enfermedades de la retina: epidemiología en España y Cataluña. Futuro e Investigación en las Enfermedades de la Retina. DMAE: Definición, tipos, síntomas, factores de riesgo. Dr. Jordi Monés. El Periódico-Novartis. Barcelona, Spain. Noviembre 18, 2014. 10.2.404.

Actualización en la Terapia para Distrofias Corio-retinianas. Dr.

Jordi Monés. Fundación José Pastor Fuertes. Valencia, Spain. December 19, 2014. 10.2.405.

Scientific Global Advisory Board Meeting. Alcon. New York.

March 20-22, 2015. 10.2.406.

RETINA I. Non–neovascular Age-related Macular Degeneration.

C. Vitae Jordi Monés 90

Debate II: Minimizing worsening of geographic atrophy. Might be feasible with Lamplaziumb. Dr. Jordi Monés. The 6th World Congress on Controversies in Ophthalmology (COPHy). Sorrento, Italy. March 31April 3, 2015. 10.2.407.

RETINA II Neovascular Age-related Macular Degeneration.

Debate I: First Line Therapy. Ranibizumab. Dr. Jordi Monés. The 6th World Congress on Controversies in Ophthalmology (COPHy). Sorrento, Italy. March 31-April 3, 2015. 10.2.408.

Retinal vein occlusions. Evaluation of ranibizumab for macular

ischemia in retinal vein occlusion: evidence from the BRIGHTER and CRYSTAL studies. Dr. Jordi Mones. Annual Meeting Abstracts. ARVO 2015. Denver, Colorado. May 07, 2015. 10.2.409.

Fovista Meeting. Barcelona. May, 15, 2015.

10.2.410.

Investigator Meeting. Steering Committee at

the International

Multicenter Clinical Trials Proxima A and Proxima B on Geographic Atrophy (Roche). Barcelona. May 21, 2015. 10.2.411.

Advisory Board Novartis. Paris, France. May 29, 2015.

10.2.412.

OCT Angiography Meeting. Roma, Italy. June 6, 2015.

10.2.413.

1st CAM Study Meeting. Capri Meeting. Italy. June 7, 2015.

10.2.414.

Global RVO Advisory Board Lucentis. Zurich, Switzerland. June

18, 2015. 10.2.415.

Anti-VEGF differentiation: The next chapter in management of

retinal diseases. Bayer Advisory Board. Nice, France. September 16, 2015. 10.2.416.

AMD and More. “Nascent” Geographic Atrophy. Dr. Jordi Monés,

Speaker and Moderator. 13th International SPECTRALIS® Symposium (ISS). Valencia, Spain. October 16, 2015.

C. Vitae Jordi Monés 91

10.2.417.

GA phenotypes with cluster analysis. Dr. Jordi Monés. The

Meeting of the European project Exploring the combined role of genetic and non-genetic factors for developing AMD: A systems level analysis of disease subgroups, risk factors, and pathways (EYE-RISK) Majorca, Spain. October 17, 2015. 10.2.418.

Effect Of Macular Ischaemia On Visual Acuity Outcomes In

Patients With Branch And Central Retinal Vein Occlusion Undergoing Individualised Treatment With Ranibizumab 0.5 Mg: Results from the BRIGHTER And CRYSTAL Studies. Poster. Dr. Jordi Monés. Second prize. 15th ESASO Retina Academy. Barcelona, Catalonia. October 23, 2015. 10.2.419.

Geographic atrophy in AMD. MasterClass Number 4. Camiel

Boon and Dr. Monés. 15th ESASO Retina Academy. Barcelona, Catalonia. October 23, 2015. 10.2.420.

Anti-VEGF vs PRP in Proliferative Diabetic Retinopathy.

Session 4. Dr. Jordi Monés, member of the Panel Discussion. 15th ESASO Retina Academy. Barcelona, Catalonia.October 23, 2015. 10.2.421.

PROXIMA EAC F2F Meeting. Steering Committee of the Roche

Clinical Trials Proxima A and Proxima B to combat atrophic AgeRelated Macular Degeneration (AMD). Dr. Jordi Monés, Member. Annual Meeting American Academy of Ophthalmology (AOO). Las Vegas. November 15, 2015. 10.2.422.

Steering Committee on exudative AMD of the Vision Academy..

Annual Meeting American Academy of Ophthalmology (AOO). Las Vegas. November 14-17, 2015. 10.2.423.

DMAE. Nuevas Perspectivas. Dr. Jordi Monés.3as Jornadas de

la SEEBV. Madrid, Spain. November 20, 2015. 10.2.424.

REONET Meeting. Zurich. December 3-4, 2015.

C. Vitae Jordi Monés 92

10.2.425.

Progresos

en

la

investigación

de

las

enfermedades

degenerativas de la retina. Dr. Jordi Monés. Asociación Mácula Retina. Sevilla, Spain. December 10, 2015. 10.2.426.

Cluster analysis for GA phenotypes. Jordi Monés/Marc Biarnés.

Big data analysis and machine based learning. Rotterdam, The Netherlands. January 22, 2016. 10.2.427.

Progression of GA. Complex Genetic Retinal Ophthalmology. J.

Mones. 6th Euretina Winter meeting 2016. Rotterdam, The Netherlands. January 23, 2016. 10.2.428.

Efficacy of ranibizumab treatment in retinal vein occlusion

patients with retinal macular ischemia: 24-month data from BRIGHTER and CRYSTAL. Dr. Monés. ARVO. Seattle. May 5th, 2016. 10.2.429.

Diagnóstico y tratamiento de las patologías maculares. Sesión

DMAE. Dr. Monés. Curso Mácula 2016. Instituto Universitario Barraquer y Universidad Autónoma de Barcelona. Barcelona (Catalonia). June, 3th, 2016.

11. THESIS 11.1.

Increased fundus autofluorescence, a biomarker of lipofuscin content, as a risk factor for the progression of geographic atrophy secondary to agerelated macular degeneration. Autor: Marc Biarnés. Jordi Monés, Director y Miembro del Tribunal. Barcelona, España. July, 2014.

11.2. Caracterización fenotípica y terapia génica del ratón Prpf31 A216p. Autora: Ana María Aramburu Del Boz. Jordi Monés, Miembro del Tribunal. Sevilla, España. December, 2015.

C. Vitae Jordi Monés 93

11.3. Desarrollo de nuevas estrategias terapéuticas para el tratamiento de enfermedades degenerativas de la retina basadas en vectores no virales y en técnicas de reprogramación celular. Autora: Ariadna R. Díaz Tahoces. Jordi Monés, Miembro del Tribunal. Elche, España. December, 2015.

12. COLLABORATION IN JOURNAL EDITION and REVIEWER 12.1. Opthalmology 12.2. Scientific Referee of “ARCHIVOS DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGIA” 12.3. Member Editoral Board Retina Today Journal 12.4. Reviewer of Journal of Ocular Pharmacology and Therapeutics.

13. SCIENTIFIC SOCIETIES MEMBERSHIP 13.1. MACULA SOCIETY (Elected in 2002) 13.2. RETINA SOCIETY (Elected Corresponding Member in 2001) 13.3. CLUB JULES GONIN (Elected 2014) 13.4. AMERICAN SOCIETY OF RETINA SPECIALISTS (Elected 2009) 13.5. AMERICAN ACADEMY OF OPHTHALMOLOGY 13.6. EURETINA SOCIETY 13.7. EUROPEAN VISION INSTITUTE 13.8. ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY 13.9. EUROPEAN ASSOCIATION FOR VISION AND EYE RESEARCH

C. Vitae Jordi Monés 94

13.10. SOCIEDAD ESPAÑOLA DE OFTALMOLOGIA 13.11. SOCIEDAD ESPAÑOLA DE RETINA VITREO 13.12. ACADÈMIA DE CIÈNCIES MÈDIQUES DE CATALUNYA I BALEARS 13.13. SOCIETAT CATALANA D'OFTALMOLOGIA 13.14. MASSACHUSETTS EYE AND EAR INFIRMARY ALUMNI 13.15. INSTITUT BARRAQUER

14. LANGUAGES 14.1. Catalan 14.2. Spanish 14.3. English